| Q86694417 | "Toxic" glaucoma? A case of possible styrene-induced ocular hypertension |
| Q38669490 | 1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads |
| Q89330797 | 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension |
| Q84476658 | 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension |
| Q82860831 | 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension |
| Q70060276 | 5 beta-Dihydrocortisol: possible mediator of the ocular hypertension in glaucoma |
| Q80114435 | A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension |
| Q35591747 | A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension |
| Q72259654 | A 3-year follow-up study of ocular hypertension by pattern electroretinogram |
| Q34274254 | A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension |
| Q83915428 | A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension |
| Q72393562 | A Chemically Induced Experimental Ocular Hypertension for Evaluating Drug Effects in Albino Rabbits |
| Q68313916 | A Clinical Trial of Metipranolol, a Noncardioselective Beta-Adrenergic Antagonist, in Ocular Hypertension |
| Q37349182 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma |
| Q91338238 | A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study |
| Q98651170 | A Minimally Invasive Experimental Model of Acute Ocular Hypertension with Acute Angle Closure Characteristics |
| Q43986038 | A Mouse Model of Chronic Ocular Hypertension Induced by Circumlimbal Suture |
| Q92626840 | A Pilot Study on the Effect of Alternate Nostril Breathing and Foot Reflexology on Intraocular Pressure in Ocular Hypertension |
| Q44948841 | A Prospective, randomized, investigator-masked evaluation of the monocular trial in ocular hypertension or open-angle glaucoma |
| Q51364249 | A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study. |
| Q57071710 | A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma |
| Q103007007 | A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma |
| Q91595617 | A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice |
| Q33765004 | A case of ocular hypertension complicated by SUNCT syndrome |
| Q43771605 | A case of optic atrophy with deep disc cupping without ocular hypertension (pseudo-glaucoma) (author's transl) |
| Q72168142 | A clinical study on water-drinking tonography. (3). Water-drinking tonography in steroid-induced ocular hypertension |
| Q39831161 | A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| Q98664356 | A comparative evaluation of segmental analysis of macular layers in patients with early glaucoma, ocular hypertension, and healthy eyes |
| Q73043513 | A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension |
| Q35314724 | A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group |
| Q32048825 | A comparison of ocular blood flow in untreated primary open-angle glaucoma and ocular hypertension |
| Q67751189 | A comparison of patient compliance in treated vs untreated ocular hypertension |
| Q73047708 | A comparison of short wavelength automated perimetry with frequency doubling perimetry for the early detection of visual field loss in ocular hypertension |
| Q43987668 | A comparison of the efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD and 0.5% levobunolol hydrochloride BID in patients with ocular hypertension or open-angle glaucoma |
| Q43868199 | A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial |
| Q43604438 | A comparison of the efficacy of betaxolol and timolol in ocular hypertension with or without adrenaline |
| Q54037226 | A comparison of the efficacy of various metipranolol-pilocarpine combinations in patients with ocular hypertension and primary open-angle glaucoma. |
| Q33410232 | A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open angle glaucoma and ocular hypertension |
| Q77139950 | A comparison of trabeculectomy with topically applied timolol in a rabbit ocular hypertension model |
| Q70240054 | A dose-response study of the effect of levobunolol on ocular hypertension |
| Q68126429 | A double-masked comparison of carteolol and timolol in ocular hypertension |
| Q31833015 | A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension |
| Q79760158 | A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension |
| Q80727630 | A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension |
| Q42107053 | A follow-up study of pupillary dynamics in patients with ocular hypertension and primary open angle glaucoma |
| Q34974671 | A laser-induced mouse model of chronic ocular hypertension to characterize visual defects |
| Q71280773 | A longitudinal study of ocular hypertension |
| Q79710537 | A low-cost optical pachymeter for the diagnosis of glaucoma and ocular hypertension |
| Q28247543 | A lymphatic defect causes ocular hypertension and glaucoma in mice |
| Q44787042 | A modified chronic ocular hypertension rat model for retinal ganglion cell neuroprotection |
| Q33931074 | A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy |
| Q94558887 | A novel rat model of ocular hypertension by a single intracameral injection of cross-linked hyaluronic acid hydrogel (Healaflow® ) |
| Q40979381 | A prospective study of ocular hypertension and glaucoma after pediatric cataract surgery |
| Q35677641 | A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study |
| Q35593945 | A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma |
| Q30958117 | A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy |
| Q79831200 | A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension |
| Q44696385 | A revisit: ocular hypertension, glaucoma suspect, preglaucoma, or glaucoma? |
| Q54412732 | A revisit: ocular hypertension, glaucoma suspect, preglaucoma, or glaucoma? |
| Q44466517 | A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma |
| Q44264227 | A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma |
| Q72221773 | A study of histology and enzymatic histochemistry on rabbit's retina in acute ocular hypertension |
| Q37221491 | A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension |
| Q43894792 | A study on susceptibility of different layers of rabbit retina to ocular hypertension |
| Q73614519 | A topical or oral carbonic anhydrase inhibitor to control ocular hypertension after cataract surgery |
| Q77215946 | ACUTE PRECOCIOUS OCULAR HYPERTENSION CAUSED BY PUPILLARY BLOCK IN PERSONS OPERATED ON FOR CATARACT. DIAGNOSIS, THERAPY AND PREVENTION |
| Q91280295 | Accuracy of Kalman Filtering in Forecasting Visual Field and Intraocular Pressure Trajectory in Patients With Ocular Hypertension |
| Q73537797 | Acetylsalicylic acid does not reduce the intraocular pressure variation in ocular hypertension or glaucoma |
| Q37257713 | Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma. |
| Q91021724 | Activation of Nrf2/HO-1 pathway protects retinal ganglion cells from a rat chronic ocular hypertension model of glaucoma |
| Q92845003 | Activation of P2X7R- NLRP3 pathway in Retinal microglia contribute to Retinal Ganglion Cells death in chronic ocular hypertension (COH) |
| Q95933502 | Activation of adenosine A3 receptor protects retinal ganglion cells from degeneration induced by ocular hypertension |
| Q102211747 | Activation of the ATP-P2X pathway by TRPV4 in acute ocular hypertension |
| Q72945238 | Acute ocular hypertension against the background of renal insufficiency |
| Q41192618 | Acute ocular hypertension disrupts barrier integrity and pump function in rat corneal endothelial cells |
| Q35631288 | Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension |
| Q46471624 | Additivity of pilocarpine to bimatoprost in ocular hypertension and early glaucoma |
| Q36021984 | Adenine nucleotides and dinucleotides as new substances for the treatment of ocular hypertension and glaucoma. |
| Q51001354 | Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. |
| Q73425563 | Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy |
| Q46041321 | Adrenaline-induced chronic ocular hypertension in adult rabbits |
| Q72421167 | Adrenergic drugs and intraocular pressure: suppression of ocular hypertension induced by water loading |
| Q89765941 | Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population |
| Q61910419 | Air-Puff Tonometry in population research – a comparison with Goldmann tonometer in individuals with suspected ocular hypertension |
| Q48100772 | Alteration of retinal intrinsic survival signal and effect of alpha2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat. |
| Q31078302 | Alterations in neurofilament light in optic nerve in rat kainate and monkey ocular hypertension models |
| Q90478316 | Altered Large-Scale Brain Functional Connectivity in Ocular Hypertension |
| Q68882352 | Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension |
| Q35885791 | An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma |
| Q67804328 | An improved model of experimentally induced ocular hypertension in the rabbit |
| Q36487013 | An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial |
| Q31890879 | An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients |
| Q80671546 | An ocular hypertension indicator (tonometer) |
| Q100474717 | An update on ripasudil for the treatment of glaucoma and ocular hypertension |
| Q82219279 | Analysis of a new visual field index, the VFI, in Ocular Hypertension and Glaucoma |
| Q42680509 | Analysis of risk factors that may be associated with progression from ocular hypertension to primary open angle glaucoma. |
| Q53872475 | Answers from the ocular hypertension treatment study. |
| Q71593258 | Antagonism of formaldehyde-induced ocular hypertension by phenylethylamines |
| Q70538573 | Antagonist of platelet-activating factor prevents prostaglandin E2 induced ocular hypertension in rabbits |
| Q69099968 | Antagonistic effect of local administration of epinephrine and phenylephrine on ocular hypertension induced by perfusion of autologous secondary aqueous humor in the rabbit |
| Q69126620 | Anterior segment autonomic dysfunction in ocular hypertension |
| Q35885784 | Applying an evidence-based approach to the management of patients with ocular hypertension: evaluating and synthesizing published evidence |
| Q43816744 | Aqueous humor flow measured by fluorophotometry. A comparative study of the effect of various beta-blocker eyedrops in patients with ocular hypertension |
| Q68694424 | Aqueous humour dynamics in ocular hypertension |
| Q33261358 | Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment. |
| Q36195614 | Argon laser-induced ocular hypertension: animal model of ocular inflammation |
| Q38841660 | Assessing Precision of Hodapp-Parrish-Anderson Criteria for Staging Early Glaucomatous Damage in an Ocular Hypertension Cohort: A Retrospective Study |
| Q100732511 | Assessment of Cerebral Vasomotor Reactivity in Patients with Primary Open Angle Glaucoma and Ocular Hypertension using the Breath-Holding Index |
| Q84513548 | Assessment of corneal biomechanical properties in normal tension glaucoma and comparison with open-angle glaucoma, ocular hypertension, and normal eyes |
| Q98613592 | Assessment of single nucleotide polymorphisms associated with steroid-induced ocular hypertension |
| Q93339447 | Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study |
| Q38088376 | Association of cytomegalovirus with idiopathic chronic anterior uveitis with ocular hypertension in Korean patients. |
| Q36016869 | Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study |
| Q43273343 | Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation |
| Q69076331 | Atypical band-shaped keratopathy associated with chronic glaucoma or ocular hypertension |
| Q33213470 | Atypical presentation of ocular hypertension following myopic LASIK |
| Q67382808 | Auto-ophthalmoscopy in experimental ocular hypertension and acute attack of glaucoma |
| Q69867098 | Autonomic neuropathy in ocular hypertension |
| Q73875870 | Autosomal-dominant megalocornea associated with ocular hypertension |
| Q33509467 | Axonal/glial upregulation of EphB/ephrin-B signaling in mouse experimental ocular hypertension |
| Q36016475 | Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up. |
| Q46034522 | Baseline risk factors for the development of primary open-angle glaucoma in the Ocular Hypertension Treatment Study. |
| Q33223207 | Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study |
| Q34550048 | Baseline visual field characteristics in the ocular hypertension treatment study. |
| Q47818076 | Basic sciences in clinical glaucoma: steroids, ocular hypertension, and glaucoma |
| Q37187224 | Bcl-2, Bcl-xL, and p-AKT are involved in neuroprotective effects of transcription factor Brn3b in an ocular hypertension rat model of glaucoma |
| Q72016322 | Benign ocular hypertension |
| Q34226897 | Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial |
| Q48667728 | Betamethasone-induced ocular hypertension in rabbits. |
| Q40300264 | Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. |
| Q88019930 | Bilateral early activation of retinal microglial cells in a mouse model of unilateral laser-induced experimental ocular hypertension |
| Q71932431 | Bilateral keratoconus with ocular hypertension and the natural cure of one eye |
| Q36599983 | Bilateral neuroinflammatory processes in visual pathways induced by unilateral ocular hypertension in the rat |
| Q33491504 | Bilateral ocular hypertension with rapidly progressive optic neuropathy in a teen |
| Q68216561 | Bilateral retinal detachment with large breaks of pars plicata associated with coloboma lentis and ocular hypertension |
| Q52995234 | Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting. |
| Q34901153 | Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting |
| Q38582444 | Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials |
| Q37030839 | Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial |
| Q33834484 | Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. |
| Q83150066 | Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension |
| Q46481642 | Bimatoprost in the treatment of ocular hypertension and chronic glaucoma |
| Q35987460 | Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials |
| Q36622405 | Bimatoprost/timolol fixed combination (BTFC) in patients with primary open angle glaucoma or ocular hypertension in Greece |
| Q28265281 | Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension |
| Q44971963 | Biochemical abnormalities associated with ocular hypertension and low tension glaucoma |
| Q33372453 | Bioinformatic and statistical analysis of the optic nerve head in a primate model of ocular hypertension |
| Q71542294 | Blindness prevention through control of ocular hypertension: an epidemiological assessment |
| Q33323004 | Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. |
| Q30994661 | Blood flow of the optic nerve head and peripapillary retina in exfoliation syndrome with unilateral glaucoma or ocular hypertension |
| Q72385780 | Blood in schlemm's canal in glaucoma suspects. A study of the relationship between blood-filling pattern and outflow facility in ocular hypertension |
| Q50797449 | Blue versus white stimuli in ocular hypertension with the Friedmann Mark 1 Visual Field Analyser |
| Q35924118 | Blue-on-yellow perimetry and corneal thickness in patients with ocular hypertension |
| Q42686419 | Blue-on-yellow visual field and retinal nerve fiber layer in ocular hypertension and glaucoma |
| Q28377582 | Bradycardia of an elderly patient caused by Timolol therapy in ocular hypertension |
| Q39401937 | Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation |
| Q22305848 | Brimonidine in the treatment of glaucoma and ocular hypertension |
| Q94696745 | Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension |
| Q94701406 | Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial |
| Q36352323 | Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study |
| Q95598864 | CADTH Canadian Drug Expert Committee Recommendation: Latanoprost (Monoprost — Laboratoires Théa): Indication: Glaucoma and Ocular Hypertension |
| Q95585521 | CADTH Canadian Drug Expert Committee Recommendation: Latanoprostene Bunod (Vyzulta — Bausch Health, Canada Inc.): Indication: For the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension |
| Q28568156 | CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway |
| Q49272910 | Calcium channels are involved in EphB/ephrinB reverse signaling‑induced apoptosis in a rat chronic ocular hypertension model. |
| Q86964309 | Calculating the "threshold to treat" in ocular hypertension |
| Q34614137 | Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade |
| Q42549955 | Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group |
| Q71758745 | Case-control study of ocular hypertension |
| Q45277827 | Cataract and ocular hypertension in children on inhaled corticosteroid therapy |
| Q41631913 | Caveolin-1 Protects Retinal Ganglion Cells against Acute Ocular Hypertension Injury via Modulating Microglial Phenotypes and Distribution and Activating AKT pathway. |
| Q90572985 | Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS) |
| Q70533617 | Central corneal endothelial cell density and central corneal thickness in ocular hypertension and primary open-angle glaucoma |
| Q74525150 | Central corneal thickness and intraocular pressure in ocular hypertension |
| Q80974311 | Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study |
| Q81844600 | Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study |
| Q64949418 | Central corneal thickness in primary open angle glaucoma, pseudoexfoliative glaucoma, ocular hypertension, and normal population. |
| Q74581947 | Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS) |
| Q81431335 | Central corneal thickness measurements in ocular hypertension, primary open angle glaucoma, glaucoma suspects and control subjects |
| Q35320502 | Central corneal thickness measurements in patients with normal tension glaucoma, primary open angle glaucoma, pseudoexfoliation glaucoma, or ocular hypertension |
| Q74151241 | Central corneal thickness, tonometry, and ocular dimensions in glaucoma and ocular hypertension |
| Q83471047 | Cerebrospinal fluid pressure in ocular hypertension |
| Q42650541 | Changes in central corneal thickness over time: the ocular hypertension treatment study. |
| Q79320053 | Changes in corneal thickness in patients with treated and untreated ocular hypertension |
| Q94705889 | Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database |
| Q43420616 | Changes in optic disc in ocular hypertension and glaucoma |
| Q44424205 | Changes in the pattern electroretinogram in glaucoma and ocular hypertension are dependent on stimulus frequency |
| Q33254819 | Changes of retinal functions following the induction of ocular hypertension in rats using argon laser photocoagulation |
| Q71402186 | Characterization of ocular hypertension induced by adenosine agonists |
| Q41894184 | Chronic ocular hypertension after treated multifocal bacterial keratitis |
| Q39695998 | Chronic ocular hypertension alters local retinal responsiveness |
| Q71735886 | Chronic ocular hypertension following episcleral venous occlusion in rats |
| Q91342642 | Chronic ocular hypertension in rabbits induced by limbal buckling |
| Q50593874 | Chronic ocular hypertension induced by circumlimbal suture in rats. |
| Q48374903 | Chronic ocular hypertension induces dendrite pathology in the lateral geniculate nucleus of the brain |
| Q50098869 | Ciliary body melanoma manifesting as unilateral ocular hypertension and early cataract. |
| Q90115935 | Cilioretinal artery obstruction, optical coherence tomography angiography, ocular hypertension, topical corticosteroid, cardiovascular risk factors |
| Q54030382 | Circulatory defects of the optic disk and retina in ocular hypertension and high pressure open-angle glaucoma. |
| Q46648253 | Classification of visual field abnormalities in the ocular hypertension treatment study. |
| Q95585650 | Clinical Review Report: Latanoprostene Bunod (Vyzulta): (Bausch Health, Canada Inc.): Indication: For the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension |
| Q95600507 | Clinical Review Report: Preservative-free latanoprost 50 μg/mL ophthalmic solution (Monoprost): (Laboratoires Théa): Indication: Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
| Q95372535 | Clinical Review Report: Travoprost 0.003% (Izba): (Novartis Pharmaceuticals Canada Inc. on behalf of Alcon Canada Inc.): Indication: reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
| Q46889757 | Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma |
| Q35208984 | Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France |
| Q33774236 | Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension |
| Q78683610 | Clinical comparison of the Berens-Tolman ocular hypertension indicator with the Schiotz tonometer |
| Q26773219 | Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension |
| Q81415833 | Clinical evaluation of the intraocular pressure in patients with glaucoma or ocular hypertension by a self-assessable tonometer |
| Q85735926 | Clinical profile of uveitis-related ocular hypertension |
| Q35075419 | Clinical relevance of the glucocorticoid receptor gene polymorphisms in glucocorticoid-induced ocular hypertension and primary open angle glaucoma |
| Q34043309 | Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension |
| Q33216538 | Cloning and screening of retina damage related genes in experimental rabbit chronic ocular hypertension |
| Q54037536 | Coexistent optic disc pit and ocular hypertension misdiagnosed as glaucoma. |
| Q44685424 | Color Doppler imaging in ocular hypertension and open-angle glaucoma |
| Q50875972 | Color pattern-reversal visual evoked potential in eyes with ocular hypertension and primary open-angle glaucoma |
| Q68095444 | Color vision defects in ocular hypertension and glaucoma. Quantification with a computer-driven color television system |
| Q24192958 | Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis |
| Q64958225 | Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta‐analysis. |
| Q26830201 | Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus |
| Q100499081 | Combined Trabeculotomy-trabeculectomy versus Trabeculectomy for Treatment of Silicone Oil-induced Ocular Hypertension |
| Q81242332 | Combined spatial, contrast, and temporal functions perimetry in mild glaucoma and ocular hypertension |
| Q95483457 | Combined spatial, contrast, and temporal functions perimetry in mild glaucoma and ocular hypertension |
| Q83812134 | Comment Re: Yu AL, Brummeisl W, Schaumberger M, Kampik A, Welge-Lussen U (2010) Vitrectomy does not increase the risk of open-angle glaucoma or ocular hypertension - a 5-year follow-up. Graefes Arch Clin Exp Ophthalmol 248:1407-1414 |
| Q33318513 | Comparative results of central corneal thickness measurements in primary open-angle glaucoma, pseudoexfoliation glaucoma, and ocular hypertension |
| Q43096323 | Comparative studies of RNFL thickness measured by OCT with global index of visual fields in patients with ocular hypertension and early open angle glaucoma |
| Q41031603 | Comparative study of atenolol and timolol in the treatment of ocular hypertension |
| Q67389005 | Comparative study of clinical course of experimental glaucoma and transitory ocular hypertension and possibility of their differential diagnosis |
| Q42660055 | Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma |
| Q53560814 | Comparing dynamic contour tonometry to Goldmann and hand-held tonometry in normal, ocular hypertension, and glaucoma populations. |
| Q33275696 | Comparing multifocal VEP and standard automated perimetry in high-risk ocular hypertension and early glaucoma |
| Q90630305 | Comparing silicone oil-induced ocular hypertension with other inducible glaucoma models in mice |
| Q92897334 | Comparison of Biomechanically Corrected Intraocular Pressure Obtained by Corvis ST and Goldmann Applanation Tonometry in Patients With Open-angle Glaucoma and Ocular Hypertension |
| Q91763375 | Comparison of Lamina Cribrosa Morphology in Eyes with Ocular Hypertension and Normal-Tension Glaucoma |
| Q38414245 | Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study |
| Q92919458 | Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension |
| Q62663750 | Comparison of a Travoprost BAK-Free Formulation Preserved with Polyquaternium-1 with BAK-Preserved Travoprost in Ocular Hypertension or Open-Angle Glaucoma |
| Q35761832 | Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients |
| Q51028831 | Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. |
| Q73654844 | Comparison of ambulatory blood pressure values in patients with glaucoma and ocular hypertension |
| Q46619242 | Comparison of confocal scanning laser ophthalmoscopy, scanning laser polarimetry and optical coherence tomography to discriminate ocular hypertension and glaucoma at an early stage |
| Q89277554 | Comparison of diagnostic capability of macular ganglion cell complex and retinal nerve fiber layer among primary open angle glaucoma, ocular hypertension, and normal population using Fourier-domain optical coherence tomography and determining their |
| Q87013335 | Comparison of dorzolamide/timolol versus brimonidine/timolol fixed combination therapy in the management of steroid-induced ocular hypertension |
| Q80657872 | Comparison of dynamic contour tonometry and noncontact tonometry in ocular hypertension and glaucoma |
| Q38398163 | Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. |
| Q33607762 | Comparison of isolated-check visual evoked potential and standard automated perimetry in early glaucoma and high-risk ocular hypertension |
| Q42556526 | Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group |
| Q35173258 | Comparison of newly diagnosed ocular hypertension and open-angle glaucoma: ocular variables, risk factors, and disease severity |
| Q33330649 | Comparison of optical coherence tomography and scanning laser polarimetry in glaucoma, ocular hypertension, and suspected glaucoma |
| Q81482758 | Comparison of rebound and applanation tonometry in the management of patients treated for glaucoma or ocular hypertension |
| Q90216338 | Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension |
| Q43738777 | Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece |
| Q73937216 | Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension |
| Q80250322 | Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension |
| Q71950237 | Comparison of topical timolol gel to oral acetazolamide in the prophylaxis of viscoelastic-induced ocular hypertension after penetrating keratoplasty |
| Q40845918 | Comparison of topically applied flurbiprofen or bromfenac ophthalmic solution on post-operative ocular hypertension in canine patients following cataract surgery |
| Q46680024 | Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost. |
| Q71079300 | Computerized visual field screening in the management of patients with ocular hypertension |
| Q73904745 | Concordance of parapapillary chorioretinal atrophy in ocular hypertension with visual field defects that accompany glaucoma development |
| Q46354216 | Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. |
| Q35322109 | Confocal Laser Scanning Tomography to Predict Visual Field Conversion in Patients With Ocular Hypertension and Early Glaucoma |
| Q37091331 | Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials |
| Q80811982 | Conjunctival modifications in ocular hypertension and primary open angle glaucoma: an in vivo confocal microscopy study |
| Q71964677 | Considerations on medical treatment with hyaluronidase in ocular hypertension caused by cortisone |
| Q71942110 | Considerations on the irreversibility of ocular hypertension caused by cortisone |
| Q73055307 | Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study |
| Q95527966 | Contrast sensitivity assessment in primary open angle glaucoma and ocular hypertension |
| Q69659956 | Contrast sensitivity changes in ocular hypertension and early glaucoma |
| Q54055117 | Contrast sensitivity in ocular hypertension and glaucoma. |
| Q96132031 | Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients, ocular hypertension and glaucoma suspect patients |
| Q91419867 | Contribution of autophagy to ocular hypertension and neurodegeneration in the DBA/2J spontaneous glaucoma mouse model |
| Q90427473 | Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension |
| Q92686877 | Corneal biomechanics and biomechanically corrected intraocular pressure in primary open-angle glaucoma, ocular hypertension and controls |
| Q86854225 | Corneal biomechanics in steroid induced ocular hypertension |
| Q36244653 | Corneal hysteresis in patients with glaucoma-like optic discs, ocular hypertension and glaucoma |
| Q30928417 | Corneal thickness and endothelial cell density measured by non-contact specular microscopy and pachymetry in Rhesus macaques (Macaca mulatta) with laser-induced ocular hypertension |
| Q53938085 | Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. |
| Q90931596 | Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension |
| Q92346298 | Correction to: Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study |
| Q98951415 | Correction to: Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study |
| Q96609724 | Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study |
| Q87613033 | Correction: Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension |
| Q42355429 | Correction: Intrasession and Between-Visit Variability of Sector Peripapillary Angioflow Vessel Density Values Measured with the Angiovue Optical Coherence Tomograph in Different Retinal Layers in Ocular Hypertension and Glaucoma |
| Q89865019 | Correction: Laser in glaucoma and ocular hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology |
| Q49434305 | Correlation between Stratus OCT and GDx VCC in early glaucoma, ocular hypertension and glaucoma suspect eyes☆. |
| Q35563013 | Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer’s disease |
| Q73556598 | Correlation between ocular hypertension induced by ibopamine and perimetric defect in primary open-angle glaucoma |
| Q37099607 | Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes |
| Q82872956 | Correlation between retinal nerve fiber layer thickness and central corneal thickness in patients with ocular hypertension: an optical coherence tomography study |
| Q37236068 | Correlation of central corneal thickness and axial length to the optic disc and peripapillary atrophy among healthy individuals, glaucoma and ocular hypertension patients |
| Q43626829 | Corticosteroid-Induced Ocular Hypertension in Pseudo-Exfoliation of Lens Capsule |
| Q95796955 | Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature |
| Q72831739 | Corticosteroid-induced ocular hypertension and range of accommodation |
| Q46394219 | Corticosteroid-induced ocular hypertension in draining molteno single-plate implants |
| Q70571488 | Corticosteroid-induced ocular hypertension in the treatment of aphakic or pseudophakic cystoid macular edema |
| Q72012703 | Cortiso;ne ocular hypertension in chronic uveitis |
| Q33398724 | Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database |
| Q67516355 | Cost of beta-adrenergic receptor blocking agents for ocular hypertension |
| Q53252924 | Cost-Effectiveness Analysis of Latanoprost Compared with Dorzolamide/Timolol Fixed Combination for the Treatment of Open-Angle Glaucoma and Ocular Hypertension Patients in Korea. |
| Q42604604 | Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist |
| Q46876356 | Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications |
| Q80021708 | Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications |
| Q44296886 | Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries |
| Q33328352 | Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database |
| Q41749208 | Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States |
| Q48337708 | Could White Coat Ocular Hypertension Affect to the Accuracy of the Diagnosis of Glaucoma? Relationships Between Anxiety and Intraocular Pressure in a Simulated Clinical Setting |
| Q69630866 | Criteria for establishing the diagnosis of open-angle glaucoma and ocular hypertension |
| Q91803467 | Current management of uveitis-associated ocular hypertension and glaucoma |
| Q96955173 | Cyclodialysis cleft repair with goniotomy for the control of post-operative ocular hypertension |
| Q77752043 | Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension |
| Q90933226 | Cystoid macular edema following selective laser trabeculoplasty in a patient with ocular hypertension |
| Q90367312 | D-Alanine Is Reduced by Ocular Hypertension in the Rat Retina |
| Q83912629 | Day-to-day variability in intraocular pressure in glaucoma and ocular hypertension |
| Q35619407 | Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension |
| Q37211044 | De novo ocular hypertension after Descemet stripping endothelial keratoplasty: comparative 3-year incidence, risk factors, and outcomes |
| Q35952899 | Decompression Retinopathy after ExPRESS Shunt Implantation for Steroid-Induced Ocular Hypertension: A Case Report |
| Q48454340 | Decrease corneal hysteresis in steroid-induced ocular hypertension: a case report. |
| Q46795376 | Decreased response of plasma cortisol to intravenous metyrapone in ocular hypertension and primary open-angle glaucoma |
| Q79624489 | Degenerative and apoptotic events at retinal and optic nerve level after experimental induction of ocular hypertension |
| Q37663860 | Delaying treatment of ocular hypertension: the ocular hypertension treatment study |
| Q87728196 | Dendritic changes in rat visual pathway associated with experimental ocular hypertension |
| Q93228484 | Densitometric profiles of optic disc hemorrhages in the Ocular Hypertension Treatment Study |
| Q36016716 | Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study |
| Q68561302 | Detection of early visual field change in ocular hypertension using STATPAC |
| Q69801963 | Detection of increased pallor over time. Computerized image analysis in untreated ocular hypertension |
| Q64082928 | Development and characterization of a new rat ocular hypertension model induced by intracameral injection of conjunctival fibroblasts |
| Q33369715 | Development of a prediction rule to estimate the probability of acceptable intraocular pressure reduction after selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension |
| Q37233253 | Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone |
| Q47198198 | Development of ocular hypertension in congenitally buphthalmic rabbits |
| Q35663108 | Development of ocular hypertension secondary to tamponade with light versus heavy silicone oil: A systematic review. |
| Q69974849 | Dexamethasone ocular hypertension and eosinopenia, and glucose tolerance test |
| Q72846753 | Dexamethasone ocular hypertension in the clinically normal eye. II. The untreated eye, outflow facility, and concentration |
| Q47333845 | Dexamethasone-Induced Ocular Hypertension in Mice: Effects of Myocilin and Route of Administration |
| Q36714628 | Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. |
| Q30248462 | Diagnosis and treatment of ocular hypertension |
| Q71212414 | Diagnostic problems in ocular hypertension |
| Q81158202 | Different responses of macrophages in retinal ganglion cell survival after acute ocular hypertension in rats with different autoimmune backgrounds |
| Q42181227 | Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma |
| Q59127771 | Diffusion Tensor Imaging Detects Microstructural Differences of Visual Pathway in Patients With Primary Open-Angle Glaucoma and Ocular Hypertension |
| Q42596910 | Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany |
| Q31877061 | Discriminating between early glaucoma and ocular hypertension: diagnostic accuracy of pattern electroretinogram and confocal scanning laser optic disc morphometry. |
| Q52736325 | Discriminatory Power of Superficial Vessel Density and Prelaminar Vascular Flow Index in Eyes With Glaucoma and Ocular Hypertension and Normal Eyes. |
| Q68098102 | Dissociation of visual deficits in ocular hypertension |
| Q81499526 | Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension |
| Q96576140 | Diurnal Measurements of Macular Thickness and Vessel Density on OCT Angiography in Healthy Eyes and Those with Ocular Hypertension and Glaucoma |
| Q90397201 | Diurnal Stability Of Peripapillary Vessel Density And Nerve Fiber Layer Thickness On Optical Coherence Tomography Angiography In Healthy, Ocular Hypertension And Glaucoma Eyes |
| Q51423651 | Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. |
| Q87973955 | Dopamine D1 receptor-mediated upregulation of BKCa currents modifies Müller cell gliosis in a rat chronic ocular hypertension model |
| Q67523016 | Dopamine, dopaminergic drugs and ocular hypertension |
| Q73465753 | Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension |
| Q49687720 | Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. |
| Q72333857 | Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension |
| Q38537039 | Drug-Induced Ocular Hypertension and Angle-Closure Glaucoma |
| Q36968704 | EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study |
| Q61816943 | Early Macular Angiography among Patients with Glaucoma, Ocular Hypertension, and Normal Subjects |
| Q87947602 | Early and frequent development of ocular hypertension in children with nephrotic syndrome |
| Q69007882 | Early diagnosis of glaucoma. II. The value of the initial examination in ocular hypertension |
| Q33465198 | Early diagnosis of ocular hypertension using a low-intensity laser irradiation test |
| Q33649865 | Early dose response analysis of ocular hypotensive effects of propranolol in patients with ocular hypertension |
| Q33996842 | Early ocular hypertension after cataract extraction |
| Q69578843 | Early ocular hypertension after cataract extraction |
| Q41981277 | Early post-traumatic ocular hypertension |
| Q92196163 | Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension |
| Q84917714 | Early treatment of ocular hypertension and glaucoma suspects (5) |
| Q90679996 | Early-Stage Ocular Hypertension Alters Retinal Ganglion Cell Synaptic Transmission in the Visual Thalamus |
| Q34881649 | Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma |
| Q34254560 | Effect of CO(2) laser sclerectomy with iridectomy on ocular hypertension in rabbits |
| Q69651519 | Effect of IOP on the visual field in ocuLar hypertension and glaucoma |
| Q35139385 | Effect of Lycium barbarum Polysaccharides on the expression of endothelin-1 and its receptors in an ocular hypertension model of rat glaucoma. |
| Q33740113 | Effect of Nogo-66 on retinal microglia in chronic ocular hypertension rats |
| Q64910443 | Effect of Ocular Hypertension on D-β-Aspartic Acid-Containing Proteins in the Retinas of Rats. |
| Q73937211 | Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension |
| Q33648337 | Effect of a beta-blocker on altered body position: induced ocular hypertension |
| Q35716460 | Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models |
| Q35942719 | Effect of adenosine on GLAST expression in the retina of a chronic ocular hypertension rat model |
| Q86675194 | Effect of ageing on the retinal vascular responsiveness to flicker light in glaucoma patients and in ocular hypertension |
| Q84472453 | Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma |
| Q72563698 | Effect of beta-adrenoblockers on prostaglandin-induced ocular hypertension in rabbits |
| Q36717120 | Effect of betaxolol on the retinal circulation in eyes with ocular hypertension: a pilot study |
| Q42594632 | Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. |
| Q34242431 | Effect of central corneal thickness on the long-term outcome of selective laser trabeculoplasty as primary treatment for ocular hypertension and primary open-angle glaucoma |
| Q41627928 | Effect of dipyridamole on prostaglandin-induced ocular hypertension in rabbits |
| Q33223546 | Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension |
| Q38383050 | Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram |
| Q41960788 | Effect of erythropoietin on the expression of HIF-1 and iNOS in retina in chronic ocular hypertension rats |
| Q33447541 | Effect of experimental ocular hypertension on macrovacuolation in Schlemm's canal endothelial cells of monkey eyes |
| Q43621110 | Effect of intracameral acetylcholine on latanoprost in preventing ocular hypertension after phacoemulsification and intraocular lens implantation |
| Q98567532 | Effect of intracameral epinephrine on heart rate, post-operative ocular hypertension, and long-term outcome following canine phacoemulsification |
| Q80378809 | Effect of locus coeruleus stimulation on ocular hypertension and pathology of pulmonary surfactant during chronic emotional stress |
| Q46957100 | Effect of ocular hypertension on retinal GABAergic activity. |
| Q80219506 | Effect of ocular hypertension on retinal nitridergic pathway activity |
| Q92848000 | Effect of ocular hypertension on the pattern of retinal ganglion cell subtype loss in a mouse model of early-onset glaucoma |
| Q33566458 | Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension |
| Q89210176 | Effect of prophylactic topical hypotensive medications in reducing the incidence of postoperative ocular hypertension after phacoemulsification in dogs |
| Q34376691 | Effect of recording duration on the diagnostic performance of multifocal visual-evoked potentials in high-risk ocular hypertension and early glaucoma. |
| Q72069747 | Effect of refractive error on the risk of ocular hypertension and open angle glaucoma |
| Q77417922 | Effect of scleral expansion band on ocular hypertension: Canadian phase 1 study |
| Q61810990 | Effect of systemic antihypertensives on change in intraocular pressure after initiating topical prostaglandins for primary open-angle glaucoma |
| Q43165352 | Effect of three treatment protocols on acute ocular hypertension after phacoemulsification and aspiration of cataracts in dogs. |
| Q74150874 | Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension |
| Q35929958 | Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group |
| Q33771719 | Effectiveness of diode laser trans-scleral cyclophotocoagulation in patients following silicone oil-induced ocular hypertension in Chinese eyes |
| Q42875379 | Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study |
| Q104688729 | Effects of Nd-YAG Laser iridotomy on anterior segment measurements in pigment dispersion syndrome and ocular hypertension |
| Q35814361 | Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial |
| Q69372206 | Effects of adrenergic agents on alpha-chymotrypsin-induced ocular hypertension in albino and pigmented rabbits: a comparative study |
| Q53975212 | Effects of adrenergics, adrenolytics, cholinergics and carbonic anhydrase inhibitors on ibopamine-induced ocular hypertension in POAG. |
| Q72550073 | Effects of befunolol ophthalmic solution, a beta-adrenergic blocking agent, on ocular hypertension and primary glaucoma |
| Q51565049 | Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. |
| Q39776669 | Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study |
| Q70260269 | Effects of indomethacin in ocular hypertension after cataract operation. A double-blind study |
| Q35587405 | Effects of ocular hypertension in the visual system of pigmented mice |
| Q51757576 | Effects of perioperative topical dorzolamide hydrochloride-timolol maleate administration on incidence and severity of postoperative ocular hypertension in dogs undergoing cataract extraction by phacoemulsification. |
| Q45296004 | Effects of pilocarpine Ocusert upon IOP, pupil diameter and refraction in patients with ocular hypertension (author's transl) |
| Q35135324 | Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis |
| Q91111303 | Efficacy And Safety Of Travoprost Versus Timolol To Treat Early-Onset Ocular Hypertension Secondary To Vitrectomy: A Randomized Trial |
| Q91781552 | Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis |
| Q36291171 | Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy |
| Q43152340 | Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment. |
| Q48429820 | Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients. |
| Q30435051 | Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension |
| Q46407913 | Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis |
| Q92066826 | Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis |
| Q42636593 | Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study |
| Q46989493 | Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand |
| Q38598695 | Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients |
| Q93606147 | Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum] |
| Q41279476 | Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study |
| Q47587175 | Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis |
| Q53119805 | Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. |
| Q93378486 | Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications |
| Q42183554 | Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis |
| Q92200992 | Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis |
| Q38244537 | Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma |
| Q43085229 | Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study |
| Q41767609 | Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations |
| Q89343448 | Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension - A three-month randomised study |
| Q77899325 | Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension |
| Q34981291 | Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study |
| Q34253481 | Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination |
| Q34492862 | Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews |
| Q44775459 | Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials |
| Q35071041 | Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials |
| Q42648057 | Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study |
| Q33892713 | Efficacy of Garcinia kola 0.5% Aqueous Eye Drops in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension |
| Q92680092 | Efficacy of Goniotomy With Kahook Dual Blade in Patients With Uveitis-associated Ocular Hypertension |
| Q89473002 | Efficacy of Repeat Selective Laser Trabeculoplasty in Medication-Naive Open-Angle Glaucoma and Ocular Hypertension during the LiGHT Trial |
| Q51555508 | Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma. |
| Q90873734 | Efficacy of a Novel Retrobulbar Extension Shunt to Rescue Eyes with Fibrotic Encapsulated Blebs and Uncontrolled Ocular Hypertension |
| Q44874866 | Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial |
| Q44382466 | Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost |
| Q95414889 | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension |
| Q101408857 | Efficacy of corneal shape index in the evaluation of ocular hypertension, primary open-angle glaucoma and exfoliative glaucoma |
| Q83449989 | Efficacy of single glaucoma medication in combined latanoprost and timolol XE therapy in patients with open-angle glaucoma and ocular hypertension: a discontinuation study |
| Q84151877 | Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension |
| Q57180780 | Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension |
| Q30992576 | Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies |
| Q100391594 | Efficacy, Drug Sensitivity, and Safety of a Chronic Ocular Hypertension Rat Model Established Using a Single Intracameral Injection of Hydrogel into the Anterior Chamber |
| Q72840296 | Electro-oculogram changes in patients with ocular hypertension and primary open-angle glaucoma |
| Q68554777 | Electrophysiological and psychophysical flicker sensitivity in patients with primary open-angle glaucoma and ocular hypertension |
| Q33511931 | Electrophysiological evidence of early functional damage in glaucoma and ocular hypertension |
| Q34995230 | Electrophysiological tests in evaluation of glaucoma and ocular hypertension treatment--up to date knowledge. A review |
| Q42607565 | Electrophysiologically determined contrast sensitivity in patients with ocular hypertension and chronic glaucoma |
| Q72459794 | Electrophysiology and psychophysics in ocular hypertension and glaucoma: evidence for different pathomechanisms in early glaucoma |
| Q45326009 | Electroretinogram and visual-evoked potential assessment of retinal and central visual function in a rat ocular hypertension model of glaucoma |
| Q91454568 | Endogenous hypercortisolism inducing reversible ocular hypertension |
| Q31045124 | Enzymatic ocular hypertension: a statistical study (author's transl) |
| Q72202938 | Enzymatic zonulolysis and postoperative ocular hypertension |
| Q68638554 | Epidemiologic and tonometric results of a multicenter study of 5,872 patients with ocular hypertension or open-angle glaucoma treated with betaxolol |
| Q71493313 | Epidemiological aspects of ocular hypertension |
| Q71493331 | Epinephrine as the initial therapy in selected cases of ocular hypertension |
| Q42332513 | Erratum to Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial |
| Q33560891 | Erratum: Modulation of microglia by Wolfberry on the survival of retinal ganglion cells in a rat ocular hypertension model |
| Q46084178 | Establishment and Characterization of an Acute Model of Ocular Hypertension by Laser-Induced Occlusion of Episcleral Veins |
| Q34326066 | Establishment of an experimental ferret ocular hypertension model for the analysis of central visual pathway damage |
| Q34635919 | Establishment of the ocular hypertension model using the common marmoset |
| Q90759731 | Estimating Ocular Hypertension and Glaucoma With Optic Nerve Tortuosity on Conventional Orbital Magnetic Resonance Imaging |
| Q83282845 | Estimation and mechanism of the destructive effects of ocular hypertension |
| Q94996134 | Estimation and mechanism of the destructive effects of ocular hypertension |
| Q57468503 | Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway |
| Q42120341 | Evaluation of Agreement between HRT III and iVue OCT in Glaucoma and Ocular Hypertension Patients |
| Q53639813 | Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis. |
| Q87297257 | Evaluation of a novel Scheimpflug-based non-contact tonometer in healthy subjects and patients with ocular hypertension and glaucoma |
| Q78401622 | Evaluation of central corneal thickness in patients affected by ocular hypertension, primary open-angle glaucoma, normal tension glaucoma |
| Q95524205 | Evaluation of central corneal thickness in patients with ocular hypertension and primary open-angle glaucoma |
| Q101556166 | Evaluation of efficacy of Aloe vera (L.) Burm. f. gel solution in methylcellulose-induced ocular hypertension in New Zealand white rabbits |
| Q85639131 | Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension |
| Q47144383 | Evaluation of spectral domain optical coherence tomography parameters in ocular hypertension, preperimetric, and early glaucoma |
| Q73905198 | Evaluation of the Berens-Tolman ocular hypertension indicator; comparative study of the Berens-Tolman ocular hypertension tonometer and the Schiotz tonometer in glaucomatous and nonglaucomatous patients |
| Q42880770 | Evaluation of the effect of bimatoprost/timolol fixed combination on ocular blood flow in patients with ocular hypertension using colour Doppler imaging. Preliminary study |
| Q31776046 | Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension |
| Q60922876 | Evidence of Hypoxic Glial Cells in a Model of Ocular Hypertension |
| Q36736039 | Evolving global risk assessment of ocular hypertension to glaucoma |
| Q37689234 | Ex-Press Mini-Implant in the Management of Ocular Hypertension Secondary to Silicone Oil Tamponed |
| Q33193307 | Experimental Mouse Ocular Hypertension: Establishment of the Model |
| Q44008241 | Experimental chronic ocular hypertension by anterior chamber injection of 0.3% carbomer solution in the rat. |
| Q40702947 | Experimental corticosteroid ocular hypertension in the rabbit |
| Q44237979 | Experimental hypertension of the ophthalmic artery and ocular hypertension (Preliminary note). |
| Q43268414 | Experimental model of ocular hypertension in the rat: study of the optic nerve capillaries and action of hypotensive drugs |
| Q74432025 | Experimental ocular hypertension in animals |
| Q92759406 | Expression and role of autophagy related protein p62 and LC3 in the retina in a rat model of acute ocular hypertension |
| Q92633610 | Expression of Melatonin and Dopamine D3 Receptor Heteromers in Eye Ciliary Body Epithelial Cells and Negative Correlation with Ocular Hypertension |
| Q46889405 | Expression of ciliary neurotrophic factor after induction of ocular hypertension in the retina of rats. |
| Q36224693 | Expression of leukemia inhibitory factor in the rat retina following acute ocular hypertension |
| Q42142406 | Expression of neuroglobin in ocular hypertension induced acute hypoxic-ischemic retinal injury in rats |
| Q69649579 | Extracapsular cataract extraction and posterior chamber implantation in primary ocular hypertension: preliminary report |
| Q36038231 | Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical Trials |
| Q45192502 | Familial occurrence of artefactual ocular hypertension from thick corneas and of primary open angle glaucoma in a French Canadian kindred |
| Q68844899 | Fast frequency electroretinogram differentiates ocular hypertension |
| Q46157425 | Features of optic disc progression in patients with ocular hypertension and early glaucoma. |
| Q69388195 | First round-table. A. Mass screening for simple glaucoma. B. The differentiation between ocular hypertension and early glaucoma with normal fields |
| Q33534044 | First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure |
| Q37239287 | First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost |
| Q53848818 | Five-year risk of progression of ocular hypertension to primary open angle glaucoma. A population-based study. |
| Q36158856 | Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study |
| Q90997796 | Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension |
| Q34188272 | Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment |
| Q38375891 | Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study |
| Q35370679 | Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis |
| Q36239886 | Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue |
| Q90288186 | Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2 |
| Q38473972 | Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study |
| Q37005971 | Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies |
| Q38226662 | Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. |
| Q35617544 | Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol |
| Q30588260 | Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products |
| Q41062355 | Flash electroretinography and pattern visual evoked potential changes in ocular hypertension patients |
| Q72505025 | Flicker perimetry using a luminance threshold strategy at frequencies from 5-25 Hz in glaucoma, ocular hypertension and normal controls |
| Q93511172 | Flicker sensitivity in treated ocular hypertension |
| Q42667775 | Flicker threshold and pattern VEP latency in ocular hypertension and glaucoma |
| Q33207420 | Flicker-evoked response measured at the optic disc rim is reduced in ocular hypertension and early glaucoma |
| Q71410534 | Fluorescein Angiography During Induced Ocular Hypertension in Man |
| Q70525745 | Fluorescein Angiography During Induced Ocular Hypertension in Retinitis Pigmentosa |
| Q67708405 | Fluorescein angiographic defects of the optic disc in ocular hypertension |
| Q93754692 | Fluorescein angiography and ocular hemodynamics. Effect of ocular pigments on choroidal fluorescence during induced ocular hypertension |
| Q42968640 | Fluorescein angiography during induced ocular hypertension in glaucoma |
| Q69456031 | Fluorescein angiography during induced ocular hypertension in pigmentary retinal dystrophy |
| Q93806120 | Fluorescein angiography in experimental ocular hypertension |
| Q66943660 | Fluorescein angiography of the optic disc in ocular hypertension and glaucoma (author's transl) |
| Q33230763 | Fluorescein filling defects of the optic nerve head in normal tension glaucoma, primary open-angle glaucoma, ocular hypertension and healthy controls |
| Q48501552 | Formaldehyde-induced ocular hypertension: the effects of polyphloretin phosphate and (plus)-catechin. |
| Q36106551 | Four-year incidence of open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study |
| Q30827151 | Free-Floating, Pigmented Cysts in the Anterior Chamber Causing Ocular Hypertension |
| Q57006322 | Frequency doubling perimetry in ocular hypertension and chronic open angle glaucoma |
| Q30841891 | Frequency doubling technique in patients with ocular hypertension and glaucoma: correlation with octopus perimeter indices. |
| Q34361690 | Frequency doubling technology, optical coherence technology and pattern electroretinogram in ocular hypertension |
| Q36773528 | From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma |
| Q99592522 | Functional and morphological alterations in a glaucoma model of acute ocular hypertension |
| Q33518577 | Functional and morphological effects of laser-induced ocular hypertension in retinas of adult albino Swiss mice. |
| Q71942556 | Further contribution concerning the action of aceclydine on ocular hypertension |
| Q71042215 | Further studies on early post-operative ocular hypertension following cataract extraction |
| Q101222481 | GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension |
| Q98209227 | Gadd45α affects retinal ganglion cell injury in chronic ocular hypertension rats by regulating p38MAPK pathway |
| Q43201833 | Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model |
| Q81401032 | Gender differences in glaucoma and ocular hypertension |
| Q33660169 | Gene expression profile determination in rat retinal tissue after ocular hypertension through oligo microarray |
| Q33679090 | Genetic heterogeneity of primary open angle glaucoma and ocular hypertension: linkage to GLC1A associated with an increased risk of severe glaucomatous optic neuropathy |
| Q40552970 | Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study |
| Q93499617 | Glaucoma and ocular hypertension |
| Q73941374 | Glaucoma and ocular hypertension in pediatric patients with cataracts |
| Q67468185 | Glaucoma versus ocular hypertension |
| Q41504886 | Glaucoma, ocular hypertension and diabetic retinopathy |
| Q42346441 | Glaucoma, ocular hypertension, cataract, and glucose tolerance |
| Q95324850 | Glaucomatous Maculopathy: Thickness Differences on Inner and Outer Macular Layers between Ocular Hypertension and Early Primary Open-Angle Glaucoma Using 8 × 8 Posterior Pole Algorithm of SD-OCT |
| Q37413609 | Glaukos iStent inject® Trabecular Micro-Bypass Implantation Associated with Cataract Surgery in Patients with Coexisting Cataract and Open-Angle Glaucoma or Ocular Hypertension: A Long-Term Study. |
| Q48250386 | GluA2 trafficking is involved in apoptosis of retinal ganglion cells induced by activation of EphB/EphrinB reverse signaling in a rat chronic ocular hypertension model. |
| Q91729475 | Glucocorticoid Receptor Transactivation Is Required for Glucocorticoid-Induced Ocular Hypertension and Glaucoma |
| Q47552785 | Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension in mice |
| Q73453441 | Glucocorticoid use and risks of ocular hypertension and glaucoma |
| Q93898850 | Glucocorticoid use and risks of ocular hypertension and glaucoma |
| Q55067091 | Glucocorticoid use and risks of ocular hypertension and glaucoma. |
| Q36692378 | Glucocorticoid-induced ocular hypertension after photorefractive keratectomy |
| Q45027989 | Glutamate-induced glutamine synthetase expression in retinal Muller cells after short-term ocular hypertension in the rat. |
| Q35166757 | Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits. |
| Q97559456 | Gonioscopic iridocorneal angle morphology and incidence of postoperative ocular hypertension and glaucoma in dogs following cataract surgery |
| Q81412488 | Graves' orbitopathy: frequency of ocular hypertension and glaucoma |
| Q35980006 | Gremlin Induces Ocular Hypertension in Mice Through Smad3-Dependent Signaling |
| Q48379512 | Group I mGluR-mediated inhibition of Kir channels contributes to retinal Müller cell gliosis in a rat chronic ocular hypertension model. |
| Q89893417 | Group II metabotropic glutamate receptor agonist promotes retinal ganglion cell survival by reducing neuronal excitotoxicity in a rat chronic ocular hypertension model |
| Q85910044 | HIF‑1 signaling pathway involving iNOS, COX‑2 and caspase‑9 mediates the neuroprotection provided by erythropoietin in the retina of chronic ocular hypertension rats |
| Q76692786 | HORMONE THERAPY AS A CAUSE OF TRANSITORY OCULAR HYPERTENSION AND GLAUCOMA |
| Q38461113 | Health care charges for patients with ocular hypertension or primary open-angle glaucoma |
| Q42596411 | Health- and vision-related quality of life in patients with ocular hypertension or primary open-angle glaucoma |
| Q33515820 | Healthcare charges in patients who transition from ocular hypertension to primary open-angle glaucoma based on ophthalmic coding data |
| Q70630351 | Hemicentral retinal vein occlusion associated with ocular hypertension and clotting abnormality |
| Q34274046 | Hemifield pattern electroretinogram in ocular hypertension: comparison with frequency doubling technology and optical coherence tomography to detect early optic neuropathy |
| Q46084635 | Herpes zoster keratouveitis and inflammatory ocular hypertension 8 years after varicella vaccination |
| Q44893817 | High-pass resolution perimetry in eyes with ocular hypertension and primary open-angle glaucoma |
| Q35933577 | Higher incidence of steroid-induced ocular hypertension in keratoconus |
| Q30845373 | Histological data on ocular hypertension caused by roentgen irradiation |
| Q35924036 | Histological observation of RGCs and optic nerve injury in acute ocular hypertension rats |
| Q36466541 | Histological study on transient ocular hypertension after laser iridotomy in rabbits |
| Q46656313 | Histology of optic nerve damage in ocular hypertension and early glaucoma |
| Q67333318 | Histomorphological changes in the eye in experimental ocular hypertension |
| Q73580100 | Hypotensive efficacy in primary open-angle glaucoma and ocular hypertension: latanoprost in monotherapy vs timolol and dorzolamide in association |
| Q31171586 | Hypothesis on the role of nutritional factors in ocular hypertension and glaucoma |
| Q92438991 | ICare Pro: Age Dependent Effect of Central Corneal Thickness on Intraocular Pressure in Glaucoma and Ocular Hypertension Patients |
| Q41700587 | INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. |
| Q43018878 | IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma |
| Q35560469 | Identification of a Novel Mucin Gene HCG22 Associated With Steroid-Induced Ocular Hypertension |
| Q46899980 | Identification of the ghrelin-GHSR 1 system and its influence in the modulation of induced ocular hypertension in rabbit and rat eyes |
| Q95822424 | Identifying outcomes that are important to patients with ocular hypertension or primary open-angle glaucoma: a qualitative interview study |
| Q53660202 | Idiopathic chronic pericarditis associated with ocular hypertension: probably an unknown combination. |
| Q91951737 | Illness perceptions in people newly diagnosed with glaucoma and ocular hypertension |
| Q26764956 | Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure |
| Q81242322 | Impaired neural conduction in crossed visual pathways in patients with ocular hypertension |
| Q42022944 | Impairment of colour vision in patients with ocular hypertension and glaucoma. With special reference to the "D and H color-rule" |
| Q85239595 | Implications of sustained elevation in extracellular ATP in retina following chronic ocular hypertension |
| Q53896997 | In response to Johnson and Zimmerman. Re: A revisit: ocular hypertension, glaucoma suspect, preglaucoma, or glaucoma? |
| Q33773467 | In vivo assessment of aqueous humor dynamics upon chronic ocular hypertension and hypotensive drug treatment using gadolinium-enhanced MRI |
| Q58777311 | In-the-bag multifocal intraocular lens causing pigment dispersion and refractory secondary ocular hypertension |
| Q90418673 | Incidence and Risk Factors of Ocular Hypertension following Pars Plana Vitrectomy and Silicone Oil Injection |
| Q93184620 | Incidence and outcomes of ocular hypertension from rhegmatogenous retinal detachment surgery in the acute postoperative setting |
| Q46063112 | Incidence and prognosis of ocular hypertension secondary to viral uveitis |
| Q84341120 | Incidence and risk factors for secondary ocular hypertension after intravitreal triamcinolone acetonide injection in Asian Indian eyes |
| Q92533132 | Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration |
| Q93377685 | Incidence of and risk factors for secondary ocular hypertension in moderate to severe infectious ulcerative keratitis |
| Q85479140 | Incidence of late-onset ocular hypertension following uncomplicated pars plana vitrectomy in pseudophakic eyes |
| Q86551370 | Incidence of late-onset ocular hypertension following uncomplicated pars plana vitrectomy in pseudophakic eyes |
| Q33932282 | Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases |
| Q47125894 | Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. |
| Q72640036 | Incidence of ocular hypertension in eyes affected by occlusion of the central vein of the retina |
| Q38239762 | Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate |
| Q80357517 | Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice |
| Q70966722 | Increased Plasma Cortisol Levels in Ocular Hypertension |
| Q73570515 | Increased corneal thickness in patients with ocular hypertension |
| Q101469694 | Increased episcleral venous pressure in a mouse model of circumlimbal suture induced ocular hypertension |
| Q45077377 | Increased plasma free cortisol in ocular hypertension and open angle glaucoma |
| Q40367561 | Indications for medical treatment of ocular hypertension and the initial use of pilocarpine |
| Q53896086 | Induced acute ocular hypertension: mode of retinal cell degeneration. |
| Q71051337 | Induced ocular hypertension prior to enucleation for choroidal melanoma |
| Q64097978 | Inflammasome Activation Induces Pyroptosis in the Retina Exposed to Ocular Hypertension Injury |
| Q36172319 | Inflammatory ocular hypertension syndrome (IOHS) in patients with syphilitic uveitis |
| Q70039610 | Influence of exfoliation syndrome on prognosis in ocular hypertension greater than or equal to 25 mm. A long-term follow-up |
| Q34738227 | Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma |
| Q73721752 | Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma |
| Q42606513 | Initial management of ocular hypertension and primary open-angle glaucoma: an evaluation of the royal college of ophthalmologists' guidelines |
| Q43513315 | Injury and ocular hypertension |
| Q78178954 | Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension |
| Q50985486 | Interlamellar flap edema due to steroid-induced ocular hypertension after laser in situ keratomileusis. |
| Q34452693 | Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study |
| Q37249233 | Intracranial pressure in primary open angle glaucoma, normal tension glaucoma, and ocular hypertension: a case-control study |
| Q100731401 | Intraocular Pressure Decrease Does Not Affect Blood Flow Rate of Ophthalmic Artery in Ocular Hypertension |
| Q73415010 | Intraocular pressure and progression in exfoliative eyes with ocular hypertension or glaucoma |
| Q46494993 | Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study |
| Q46219246 | Intraocular pressure lowering, change of antiapoptotic molecule expression, and neuroretinal changes by dorzolamide 2%/timolol 0.5% combination in a chronic ocular hypertension rat model |
| Q70793176 | Intraocular pressure of rhesus monkeys (Macaca mulatta) II. Juvenile ocular hypertension and its apparent relationship to ocular growth |
| Q96642635 | Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study |
| Q91333010 | Intraocular pressure-lowering effects of imidazo[1,2-a]- and pyrimido[1,2-a]benzimidazole compounds in rats with dexamethasone-induced ocular hypertension |
| Q43931556 | Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study |
| Q35102806 | Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China |
| Q36107003 | Intrasession and Between-Visit Variability of Sector Peripapillary Angioflow Vessel Density Values Measured with the Angiovue Optical Coherence Tomograph in Different Retinal Layers in Ocular Hypertension and Glaucoma |
| Q53822533 | Intravenous Hypertonic Saline to Lower Intraocular Pressure in Ocular Hypertension and Primary Open-angle and Exfoliation Glaucoma. |
| Q38934012 | Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma |
| Q81297442 | JAK/STAT pathway mediates retinal ganglion cell survival after acute ocular hypertension but not under normal conditions |
| Q86694423 | Juvenile onset of ocular hypertension associated with de novo nail-patellar syndrome |
| Q97594255 | Kahook Dual Blade goniotomy in post penetrating keratoplasty steroid-induced ocular hypertension |
| Q52657473 | Knockout of tissue transglutaminase ameliorates TGFβ2-induced ocular hypertension: A novel therapeutic target for glaucoma? |
| Q91222917 | LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY: A Multicenter Study of 6,048 Eyes |
| Q77098149 | Lack of long-term drift in timolol's effectiveness in patients with ocular hypertension |
| Q40042636 | Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology |
| Q32107152 | Laser scanning tomography of the optic nerve head in ocular hypertension and glaucoma |
| Q33383220 | Laser-induced chronic ocular hypertension model on SD rats |
| Q35541085 | Laser-induced ocular hypertension in adult rats does not affect non-RGC neurons in the ganglion cell layer but results in protracted severe loss of cone-photoreceptors. |
| Q33509472 | Laser-induced ocular hypertension in albino CD-1 mice |
| Q82945033 | Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma |
| Q44827563 | Latanoprost therapy in patients with glaucoma and ocular hypertension inadequately controlled with carteolol |
| Q73538862 | Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation |
| Q79954836 | Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension |
| Q45991237 | Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. |
| Q46237233 | Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study |
| Q55022142 | Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. |
| Q90916809 | Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension |
| Q34981213 | Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial |
| Q34181305 | Latrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma |
| Q69881271 | Levobunolol vs timolol for open-angle glaucoma and ocular hypertension |
| Q69885550 | Levobunolol. A three-month efficacy study in the treatment of glaucoma and ocular hypertension |
| Q37250462 | Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study |
| Q40388842 | Long-term activation of c-Fos and c-Jun in optic nerve head astrocytes in experimental ocular hypertension in monkeys and after exposure to elevated pressure in vitro |
| Q35200693 | Long-term effect of laser-induced ocular hypertension on the cone electroretinogram and central macular thickness in monkeys |
| Q33687798 | Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study |
| Q92243216 | Long-term effectiveness and safety of trabecular microbypass stent implantation with cataract surgery in patients with glaucoma or ocular hypertension: Five-year outcomes |
| Q73372693 | Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial |
| Q46487338 | Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. |
| Q52672712 | Long-term evaluation of ocular hypertension with primary angle closure and primary open angles. |
| Q104468106 | Long-term incidence and risk factors of ocular hypertension following Dexamethasone-implant injections. The SAFODEX-2 study |
| Q33764018 | Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma |
| Q37890232 | Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches |
| Q37555962 | Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study. |
| Q99207552 | Longitudinal assessment of optic nerve head changes using optical coherence tomography in a primate microbead model of ocular hypertension |
| Q36379964 | Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment |
| Q50780800 | Longitudinal comparison of temporal-modulation perimetry with white-on-white and blue-on-yellow perimetry in ocular hypertension and early glaucoma. |
| Q91942931 | Longitudinal detection of retinal alterations by visible and near-infrared optical coherence tomography in a dexamethasone-induced ocular hypertension mouse model |
| Q33240730 | Longitudinal non-invasive proton NMR spectroscopy measurement of vitreous lactate in a rabbit model of ocular hypertension |
| Q97089193 | Longitudinal outcomes of circumlimbal suture model-induced chronic ocular hypertension in Sprague-Dawley albino rats |
| Q34409913 | Longitudinal stability of the diurnal rhythm of intraocular pressure in subjects with healthy eyes, ocular hypertension and pigment dispersion syndrome |
| Q72753252 | Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma |
| Q33643760 | Low-contrast letter charts in early diabetic retinopathy, ocular hypertension, glaucoma, and Parkinson's disease |
| Q91853949 | Lycium Barbarum Polysaccharides Rescue Neurodegeneration in an Acute Ocular Hypertension Rat Model Under Pre- and Posttreatment Conditions |
| Q96771641 | Lycium barbarum polysaccharides related RAGE and Aβ levels in the retina of mice with acute ocular hypertension and promote maintenance of blood retinal barrier |
| Q83851182 | Lysosomal degradation of retinal glial AQP4 following its internalization induced by acute ocular hypertension |
| Q42623076 | Macular colour contrast sensitivity in ocular hypertension and glaucoma: evidence for two types of defect |
| Q33196414 | Management of ocular hypertension |
| Q93668415 | Management of ocular hypertension |
| Q53957215 | Management of ocular hypertension and open angle glaucoma: clinical practice and computer-assisted decision-making. |
| Q40616744 | Management of ocular hypertension and primary open angle glaucoma |
| Q35598602 | Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study |
| Q79450399 | Management of patients with ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study |
| Q38603572 | Manganese porphyrin reduces retinal injury induced by ocular hypertension in rats |
| Q91865970 | Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension |
| Q33253341 | Measurement of autofluorescence in the parapapillary atrophic zone in patients with ocular hypertension |
| Q93651421 | Measurements of reversibility of optic disc cupping and pallor in ocular hypertension and glaucoma |
| Q52542265 | Measuring contrast sensitivity in patients with Graves' ophthalmopathy complicated by ocular hypertension and suspect glaucoma or dysthyroid optic neuropathy. |
| Q45045931 | Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma |
| Q41027486 | Mechanisms in ocular hypertension |
| Q51105196 | Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study. |
| Q24243220 | Medical interventions for primary open angle glaucoma and ocular hypertension |
| Q24246992 | Medical interventions for primary open angle glaucoma and ocular hypertension |
| Q87992257 | Medical management of acute ocular hypertension in a western screech owl (Megascops kennicottii) |
| Q34546912 | Melanopsin-Containing or Non-Melanopsin-Containing Retinal Ganglion Cells Response to Acute Ocular Hypertension With or Without Brain-Derived Neurotrophic Factor Neuroprotection. |
| Q30818410 | Melanopsin-expressing retinal ganglion cells are more injury-resistant in a chronic ocular hypertension model. |
| Q35762849 | Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. |
| Q24672885 | Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension |
| Q96957868 | Metabolic Syndrome is Associated with Ocular Hypertension and Glaucoma |
| Q73006540 | Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension |
| Q52594562 | Methods to Induce Chronic Ocular Hypertension: Reliable Rodent Models as a Platform for Cell Transplantation and Other Therapies. |
| Q91003314 | Methyl 3,4-dihydroxybenzoate protects retina in a mouse model of acute ocular hypertension through multiple pathways |
| Q104795098 | MicroRNA-93/STAT3 signalling pathway mediates retinal microglial activation and protects retinal ganglion cells in an acute ocular hypertension model |
| Q34340485 | Mid-term evaluation of the new Glaukos iStent with phacoemulsification in coexistent open-angle glaucoma or ocular hypertension and cataract |
| Q79963480 | Midterm response with latanoprost therapy in german ocular hypertension patients |
| Q69881274 | Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension |
| Q44939325 | Modeling of LIM-Kinase 2 inhibitory activity of pyrrolopyrimidine analogues: useful in treatment of ocular hypertension and glaucoma. |
| Q37296829 | Modulation of microglia by Wolfberry on the survival of retinal ganglion cells in a rat ocular hypertension model |
| Q40219288 | Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective |
| Q33359419 | Morpho-functional follow-up of the optic nerve in treated ocular hypertension: disc morphometry and steady-state pattern electroretinogram. |
| Q36911620 | Morphological and functional changes in experimental ocular hypertension and role of neuroprotective drugs |
| Q72576985 | Morphological studies of the effect of beta-blocker in drug induced ocular hypertension. 2. Ocular hypertension following the topical application of prostaglandin E2 |
| Q73008141 | Motion perimetry identifies nerve fiber bundlelike defects in ocular hypertension |
| Q61818354 | Mouse model of ocular hypertension with retinal ganglion cell degeneration |
| Q73841477 | Movement detection threshold and ocular hypertension |
| Q91581586 | Mucoadhesive olaminosomes: A novel prolonged release nanocarrier of agomelatine for the treatment of ocular hypertension |
| Q56542779 | Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension |
| Q33312906 | Multifocal electroretinographical changes in monkeys with experimental ocular hypertension: a longitudinal study |
| Q36730478 | Mutant human myocilin induces strain specific differences in ocular hypertension and optic nerve damage in mice |
| Q46601879 | Myocilin gene expression in the trabecular meshwork of rats in a steroid-induced ocular hypertension model |
| Q84526655 | NICE guidance on managing chronic open angle glaucoma and ocular hypertension |
| Q72519116 | Nadolol eye drops in glaucoma and ocular hypertension: A controlled clinical study of dose response and duration of action |
| Q42647239 | Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years |
| Q57101147 | Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years |
| Q42607227 | Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. |
| Q68005504 | Nerve fiber layer and optic disc fluorescein defects in glaucoma and ocular hypertension |
| Q74080070 | Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension |
| Q92014847 | Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension |
| Q101223650 | Netarsudil for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Literature Review |
| Q91411624 | Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension |
| Q90480617 | Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension |
| Q73186739 | Neural conduction in the visual pathways in ocular hypertension and glaucoma |
| Q92521760 | Neuronal Epac1 mediates retinal neurodegeneration in mouse models of ocular hypertension |
| Q90615302 | Neuronal apoptosis, axon damage and synapse loss occur synchronously in acute ocular hypertension |
| Q52728892 | Neuroprotection of Transplanting Human Umbilical Cord Mesenchymal Stem Cells in a Microbead Induced Ocular Hypertension Rat Model. |
| Q30759666 | Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension |
| Q46305594 | Neuroprotective effect of 5ɑ-androst-3β,5,6β-triol on retinal ganglion cells in a rat chronic ocular hypertension model |
| Q33260576 | Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma |
| Q50282813 | Neuroprotective effects of intravitreally transplanted adipose tissue and bone marrow-derived mesenchymal stem cells in an experimental ocular hypertension model. |
| Q35063022 | Neuroprotective effects of transcription factor Brn3b in an ocular hypertension rat model of glaucoma |
| Q68006302 | Neuroretinal rim area measurements by configuration and by pallor in ocular hypertension and glaucoma |
| Q63290551 | New furoxan derivatives for the treatment of ocular hypertension |
| Q50455787 | Nitric oxide levels in the aqueous humor vary in different ocular hypertension experimental models. |
| Q53822538 | Non-invasive Detection of Mitochondrial Dysfunction in Ocular Hypertension and Primary Open-angle Glaucoma. |
| Q34729323 | Nonarteritic ischemic optic neuropathy secondary to severe ocular hypertension masked by interface fluid in a post-LASIK eye. |
| Q36122955 | Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review |
| Q92535732 | Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension |
| Q88164516 | Noninvasive evaluation of cerebrospinal fluid pressure in ocular hypertension: a preliminary study |
| Q28338445 | Norepinephrine in Treatment of Ocular Hypertension and Glaucoma |
| Q35688374 | Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. |
| Q43260890 | Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma |
| Q38323142 | Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes |
| Q92554854 | Nuclear factor-kappa beta signaling is required for transforming growth factor Beta-2 induced ocular hypertension |
| Q39644204 | Nutritional, lifestyle and environmental factors in ocular hypertension and primary open-angle glaucoma: an exploratory case-control study |
| Q45939532 | OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT. |
| Q57292291 | OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE |
| Q38828562 | OCULAR HYPERTENSION AND GLAUCOMA FOLLOWING VITRECTOMY: A Systematic Review |
| Q77197362 | ON ACTION OF INSTILLATION OF GUANETHIDINE ON EXPERIMENTAL OCULAR HYPERTENSION IN THE RABBIT |
| Q35327935 | Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review |
| Q50788779 | Observations on color vision testing in ocular hypertension and glaucoma |
| Q100502739 | Obstructive sleep apnea as a risk factor for primary open angle glaucoma and ocular hypertension in a monocentric pilot study |
| Q41965958 | Occurrence and management of ocular hypertension and secondary glaucoma in juvenile idiopathic arthritis-associated uveitis: An observational series of 104 patients |
| Q40838895 | Occurrence of and Risk Factors for Ocular Hypertension and Secondary Glaucoma in Juvenile Idiopathic Arthritis-associated Uveitis |
| Q71779208 | Ocular Circulation: Analysis of the Effect of Induced Ocular Hypertension on Retinal and Choroidal Blood Flow in Man |
| Q69399333 | Ocular Hemodynamics During Induced Ocular Hypertension in Man |
| Q98464859 | Ocular Hypertension Drives Remodeling of AMPA Receptors in Select Populations of Retinal Ganglion Cells |
| Q95392709 | Ocular Hypertension Following Intravenous Infusion of Prostaglandin E1 |
| Q38260493 | Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide |
| Q94445333 | Ocular Hypertension Following Intravitreal Injection of 0.7mg Dexamethasone Implant versus 2mg Triamcinolone |
| Q54011894 | Ocular Hypertension Following Use of an Antral Balloon |
| Q34213773 | Ocular Hypertension Induced by Air in the Anterior Chamber |
| Q54494160 | Ocular Hypertension Requiring Suspension of Inhaled Corticosteroids. |
| Q83319316 | Ocular Hypertension Treatment Study |
| Q35108068 | Ocular Hypertension Treatment Study (OHTS) commentary |
| Q57337616 | Ocular Hypertension and Secondary Glaucoma in Children with Uveitis |
| Q91704886 | Ocular Hypertension in Adults with a History of Prematurity |
| Q97536310 | Ocular Hypertension, Glaucoma or Compressive Neuropathy in Patient with Active TED |
| Q38503499 | Ocular Hypertension: Reasons for Abandonment of the Term |
| Q31050790 | Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension |
| Q77356702 | Ocular hypertension after a triple procedure: phacoemulsification, intraocular lens implantation, and scleral buckling surgery |
| Q36846375 | Ocular hypertension after cataract surgery: a comparison of three surgical techniques and two viscoelastics. |
| Q35671057 | Ocular hypertension after intravitreal steroid injections: Clinical update as of 2015 |
| Q41894162 | Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification |
| Q34904457 | Ocular hypertension after pediatric cataract surgery: baseline characteristics and first-year report |
| Q73212568 | Ocular hypertension and central corneal thickness |
| Q46706899 | Ocular hypertension and corneal thickness: a long-term prospective study. Results after two years. |
| Q39869321 | Ocular hypertension and diabetes mellitus in the Beijing Eye Study |
| Q70228191 | Ocular hypertension and endothelio-iridic dystrophic syndromes. Nosologic discussion |
| Q46891550 | Ocular hypertension and glaucoma |
| Q66912437 | Ocular hypertension and glaucoma |
| Q33812754 | Ocular hypertension and glaucoma associated with scleritis and uveitis. Aspects of epidemiology, pathogenesis and therapy |
| Q84163951 | Ocular hypertension and glaucoma in Graves' orbitopathy |
| Q43713185 | Ocular hypertension and glaucoma incidence in patients with scleritis |
| Q54025975 | Ocular hypertension and glaucomatous optic nerve damage. |
| Q30362043 | Ocular hypertension and hypotony as determinates of outcomes in uveitis |
| Q46466992 | Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents |
| Q84353156 | Ocular hypertension and normal-tension glaucoma: time for banishment and burial |
| Q33642597 | Ocular hypertension and posture |
| Q53981590 | Ocular hypertension and primary open-angle glaucoma: a comparative study of their retrobulbar blood flow velocity. |
| Q96608193 | Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases |
| Q33650754 | Ocular hypertension and systemic responses to the water-drinking test |
| Q38092599 | Ocular hypertension and the risk of blindness |
| Q37034323 | Ocular hypertension associated with ocular sarcoidosis |
| Q37404057 | Ocular hypertension associated with simple goitre observed in young individuals |
| Q72713988 | Ocular hypertension due to cortisone |
| Q98775609 | Ocular hypertension following 40 mg sub-Tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinolone |
| Q36613411 | Ocular hypertension following Nd:YAG laser capsulotomy: a potentially blinding complication |
| Q50990996 | Ocular hypertension following cataract surgery in dogs: 139 cases (1992-1993). |
| Q38062429 | Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents |
| Q33511068 | Ocular hypertension impairs optic nerve axonal transport leading to progressive retinal ganglion cell degeneration |
| Q104581272 | Ocular hypertension in Axenfeld-Rieger Syndrome |
| Q46871418 | Ocular hypertension in mice with a targeted type I collagen mutation |
| Q90479166 | Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management |
| Q41610145 | Ocular hypertension in primary glaucoma: a new hypothesis |
| Q67961389 | Ocular hypertension in radiologists and radiology technicians |
| Q77633399 | Ocular hypertension in renal transplant recipients |
| Q72688206 | Ocular hypertension in the diabetic |
| Q75450266 | Ocular hypertension induced by air in the anterior chamber |
| Q75731086 | Ocular hypertension induced by air in the anterior chamber |
| Q67266302 | Ocular hypertension induced by scleral suction cup |
| Q42636664 | Ocular hypertension induced by tropicamide after treatment of the angle with argon laser |
| Q70710669 | Ocular hypertension induced with dexamethasone and basic pressure of the normal human eye |
| Q92075782 | Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience |
| Q43655721 | Ocular hypertension or early glaucoma? |
| Q39698277 | Ocular hypertension or early undetected glaucoma? |
| Q35547864 | Ocular hypertension results in retinotopic alterations in the visual cortex of adult mice. |
| Q68278658 | Ocular hypertension revealing sarcoidosis |
| Q91009515 | Ocular hypertension secondary to high endogenous steroid load in Cushing's disease |
| Q93003843 | Ocular hypertension secondary to obesity: cortisol, the missing piece of the pathophysiological puzzle? |
| Q95828197 | Ocular hypertension suppresses homeostatic gene expression in optic nerve head microglia of DBA/2 J mice |
| Q80332441 | Ocular hypertension treatment study |
| Q53858808 | Ocular hypertension treatment study results could be misconstrued. |
| Q84917736 | Ocular hypertension treatment study: design issues |
| Q68842948 | Ocular hypertension, glaucoma suspect, preglaucoma, or glaucoma? Synopsis of views |
| Q42644321 | Ocular hypertension: 12 years' follow-up. |
| Q42021748 | Ocular hypertension: a comparative follow-up of black and white patients |
| Q35460478 | Ocular hypertension: an approach to assessment and management |
| Q44326820 | Ocular hypertension: correlation of anterior chamber angle width and risk of progression to glaucoma |
| Q35885780 | Ocular hypertension: defining risks and clinical options |
| Q33837896 | Ocular hypertension: general characteristics and estimated cerebrospinal fluid pressure. The Beijing Eye Study 2011 |
| Q67560385 | Ocular hypertension: to treat or not to treat |
| Q72743168 | Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma |
| Q83329970 | Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study |
| Q80471429 | Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension |
| Q79710699 | Ocular response analyser to assess hysteresis and corneal resistance factor in low tension, open angle glaucoma and ocular hypertension |
| Q34357225 | Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost |
| Q37866329 | Ocular surface disease in patients with ocular hypertension and glaucoma |
| Q64889077 | Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chlori |
| Q86333539 | Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension |
| Q42610115 | Ocular sympathetic denervation associated with ocular hypertension: a case report |
| Q96351194 | Omidenepag Isopropyl Versus Latanoprost in Primary Open-angle Glaucoma and Ocular Hypertension: ThePhase 3 AYAME Study |
| Q93098091 | Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension |
| Q68635996 | On a possibility to connect quantitatively ocular hypertension and damage to the optic nerve |
| Q72663380 | On ocular hypertension secondary to local corticosteroid therapy. (Clinical contribution) |
| Q71914562 | On the favorable incidence of ocular hypertension on the reapplication of the detached retina |
| Q67315101 | On the mechanism of corticosteroid-induced ocular hypertension |
| Q64097409 | One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study |
| Q70446011 | Open angle glaucoma, ocular hypertension, low-tension glaucoma, and refraction |
| Q42640292 | Open-angle glaucoma and ocular hypertension: the Long Island Glaucoma Case-control Study |
| Q64116734 | Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses |
| Q33193308 | Optic Nerve Damage in Experimental Mouse Ocular Hypertension |
| Q71589740 | Optic disc asymmetry. A sign of ocular hypertension |
| Q71493320 | Optic disc changes in ocular hypertension |
| Q71022083 | Optic disc haemorrhages precede retinal nerve fibre layer defects in ocular hypertension |
| Q37095149 | Optic disc hemorrhages in glaucoma and ocular hypertension: implications and recommendations |
| Q69651540 | Optic disc pallor and visual field defect in exfoliative and non-exfoliative, untreated ocular hypertension |
| Q72560796 | Optic nerve axon count and axon diameter in patients with ocular hypertension and normal visual fields |
| Q90715922 | Optic nerve head diurnal vessel density variations in glaucoma and ocular hypertension measured by optical coherence tomography angiography |
| Q42019976 | Optic neuropathy and increased retinal glial fibrillary acidic protein due to microbead-induced ocular hypertension in the rabbit. |
| Q36936740 | Optical Quality and Related Factors in Ocular Hypertension: Preliminary Study |
| Q95262185 | Optical coherence tomography angiography of the peripapillary region and macula in normal, primary open angle glaucoma, pseudoexfoliation glaucoma and ocular hypertension eyes |
| Q53031530 | Optimum Technique of Light Brightness Assessment in Control Subjects and Patients with Ocular Hypertension and Glaucoma |
| Q108792411 | Optogenetic Modulation of Intraocular Pressure in a Glucocorticoid-Induced Ocular Hypertension Mouse Model |
| Q36871124 | Oral Contraceptive Use and Prevalence of Self-Reported Glaucoma or Ocular Hypertension in the United States. |
| Q37257783 | Oral versus topical carbonic anhydrase inhibitors in ocular hypertension after scleral tunnel cataract surgery |
| Q85856394 | Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? |
| Q39432089 | Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey |
| Q96687201 | Outcome of Selective Laser Trabeculoplasty in Young Patients with Primary Open-Angle Glaucoma and Ocular Hypertension |
| Q47365551 | P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model |
| Q37401930 | PREVENTION OF EXPERIMENTAL OCULAR HYPERTENSION WITH POLYPHLORETIN PHOSPHATE |
| Q61627832 | PSS4 Longer Term Patient Benefits of Polyquad® Preservative Instead of Benzalkonium Chloride in Prostaglandin Eye Drops: A Microsimulation Model in Ocular Hypertension and Open-Angle Glaucoma |
| Q33543588 | Papillary retinal nerve fiber layer thickness measurement using optical coherence tomography in children with ocular hypertension and juvenile glaucoma |
| Q68188937 | Parasympathetic denervation hypersensitivity of the iris in ocular hypertension |
| Q104476294 | Pars Plana Vitrectomy and the Risk of Ocular Hypertension and Glaucoma: Where Are We? |
| Q46293545 | Pathological changes of retinal glial cells in a rat chronic ocular hypertension model |
| Q89712886 | Pathophysiology and management of glaucoma and ocular hypertension related to trauma |
| Q39458214 | Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution |
| Q93920112 | Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma |
| Q52869236 | Patients with ocular hypertension have abnormal point scotopic thresholds in the superior hemifield. |
| Q59280908 | Pattern ERG as an Early Glaucoma Indicator in Ocular Hypertension: A Long-Term, Prospective Study |
| Q78106733 | Pattern electroretinogram and optic nerve topography in ocular hypertension |
| Q39708222 | Pattern electroretinogram and peripheral colour contrast thresholds in ocular hypertension and glaucoma: comparison and correlation of results. |
| Q69444266 | Pattern electroretinogram as a function of spatial frequency in ocular hypertension and early glaucoma |
| Q69471899 | Pattern electroretinogram in glaucoma and ocular hypertension |
| Q70830308 | Pattern electroretinogram in treated ocular hypertension: a cross-sectional study after timolol maleate therapy |
| Q54104735 | Pattern electroretinogram recorded by skin electrodes in early ocular hypertension and glaucoma. |
| Q67928617 | Pattern electroretinograms in ocular hypertension |
| Q33222517 | Pattern electroretinography in a rat model of ocular hypertension: functional evidence for early detection of inner retinal damage. |
| Q54127511 | Pattern reversal electroretinogram (PRERG) abnormalities in ocular hypertension: correlation with glaucoma risk factors. |
| Q35522213 | Perfusion-cultured bovine anterior segments as an ex vivo model for studying glucocorticoid-induced ocular hypertension and glaucoma |
| Q41029445 | Peripapillary Choroidal Thickness and Choroidal Area in Glaucoma, Ocular Hypertension and Healthy Subjects by SD-OCT. |
| Q69950021 | Peripapillary crescents and halos in normal-tension glaucoma and ocular hypertension |
| Q73889249 | Peripheral colour contrast thresholds in ocular hypertension and glaucoma |
| Q70710665 | Peripheral depth of the anterior chamber of the eye in normal humans and in subjects with ocular hypertension induced with dexamethasone |
| Q53586322 | Peripheral retinal ischemia following posttraumatic ocular hypertension in the setting of sickle cell trait. |
| Q81121930 | Persisent ocular hypertension following intravitreal ranibizumab |
| Q37212764 | Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005. |
| Q52598855 | Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. |
| Q71493310 | Perspectives on ocular hypertension, New York, New York, December 7, 1979 |
| Q91855148 | Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant |
| Q95585654 | Pharmacoeconomic Review Report: Latanoprostene Bunod (Vyzulta): (Bausch Health, Canada Inc.): Indication: For the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension |
| Q95599536 | Pharmacoeconomic Review Report: Preservative-free latanoprost 50 μg/mL ophthalmic solution (Monoprost): (Laboratoires Théa): Indication: For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
| Q95372618 | Pharmacoeconomic Review Report: Travoprost 0.003% (Izba): (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.): Indication: The reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
| Q33300609 | Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension |
| Q38052295 | Pharmacological management of ocular hypertension: current approaches and future prospective |
| Q28372035 | Pharmacological validation of a feline model of steroid-induced ocular hypertension |
| Q83385980 | Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma |
| Q92158699 | Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension |
| Q96438275 | Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) |
| Q79550516 | Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension |
| Q72353878 | Photocoagulation and local steroid-induced ocular hypertension in the treatment of diabetic retinopathy |
| Q41031130 | Photogrammetry of the optic disc in glaucoma and ocular hypertension with simultaneous stereo photography |
| Q70992051 | Pilocarpine, carbachol and carteolol on open-angle glaucoma and ocular hypertension (author's transl) |
| Q98622892 | Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients with Open-angle Glaucoma or Ocular Hypertension |
| Q30885068 | Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension |
| Q69694162 | Possibly reduced prevalence of peripapillary crescents in ocular hypertension |
| Q33222957 | Posterior pole retinal thickness in ocular hypertension and glaucoma: early changes detected by hemispheric asymmetries |
| Q91396481 | Posttreatment Intervention With Lycium Barbarum Polysaccharides is Neuroprotective in a Rat Model of Chronic Ocular Hypertension |
| Q42623214 | Postural change of intraocular and blood pressures in ocular hypertension and low tension glaucoma |
| Q37294230 | Postural studies in pulsatile ocular blood flow: I. Ocular hypertension and normotension |
| Q46738513 | Practical assessment. Ocular hypertension |
| Q98228476 | Predicting factors of ocular hypertension following keratoplasty: Indications versus the procedure |
| Q42601956 | Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study |
| Q70659697 | Predictive value of the pattern electroretinogram in high-risk ocular hypertension |
| Q42665477 | Predictors and outcomes of ocular hypertension after open-globe injury |
| Q92976466 | Predictors of selective laser trabeculoplasty success in open angle glaucoma or ocular hypertension: does baseline tonography have a predictive role? |
| Q36627716 | Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension |
| Q37257696 | Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma |
| Q43799914 | Preoperative latanoprost to prevent ocular hypertension after phacoemulsification and intraocular lens implantation |
| Q39348004 | Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice |
| Q33803702 | Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study |
| Q87647004 | Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial |
| Q90726131 | Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages |
| Q42228049 | Prevalence and aetiology of ocular hypertension in acute and chronic uveitis |
| Q84448763 | Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension |
| Q52930332 | Prevalence of Ocular Hypertension and Glaucoma as Well as Associated Factors in Graves' Orbitopathy. |
| Q89877996 | Prevalence of Unknown Ocular Hypertension, Glaucoma Suspects, and Glaucoma in Patients Seen in an Ophthalmology Center in France |
| Q36829097 | Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease |
| Q42632667 | Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study |
| Q81089411 | Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy |
| Q44219101 | Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy. |
| Q100431633 | Prevalence, risk factors and management of ocular hypertension or glaucoma in patients with Vogt-Koyanagi-Harada disease |
| Q83319320 | Preventing glaucoma in a high-risk population: impact and observations of the Ocular Hypertension Treatment Study |
| Q40523642 | Prevention of postoperative ocular hypertension by prostaglandin inhibitors |
| Q95722372 | Primary Care Screening for Ocular Hypertension and Primary Open-Angle Glaucoma |
| Q91561029 | Primary Selective Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success, and Safety from the Laser in Glaucoma and Ocular Hypertension Trial |
| Q70038627 | Principles of outpatient follow-up in ocular hypertension |
| Q94476303 | Prioritizing outcome preferences in patients with ocular hypertension and open-angle glaucoma using best-worst scaling |
| Q39685256 | Prognostic significance of the pattern visual evoked potential in ocular hypertension |
| Q90687948 | Progression from ocular hypertension to visual field loss in the English hospital eye service |
| Q87849881 | Progressive Bilateral Scleral Pigmentation in a Patient With Ocular Hypertension |
| Q100697588 | Prolonged use of nitric oxide donor sodium nitroprusside induces ocular hypertension in mice |
| Q38787393 | Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence |
| Q37444732 | Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety |
| Q42647710 | Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety |
| Q52580209 | Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. |
| Q36561051 | Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence |
| Q34456143 | Protection of retinal ganglion cells and retinal vasculature by Lycium barbarum polysaccharides in a mouse model of acute ocular hypertension |
| Q90353670 | Protection of the Retinal Ganglion Cells: Intravitreal Injection of Resveratrol in Mouse Model of Ocular Hypertension |
| Q91818433 | Protective effects of carnosic acid on retinal ganglion cells in acute ocular hypertension rats |
| Q28578850 | Proteomic analysis of rat retina in a steroid-induced ocular hypertension model: potential vulnerability to oxidative stress |
| Q33307684 | Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: downregulation of type I collagen C-propeptides. |
| Q53355880 | Psychometric Validation of the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25) French version: in a population of patients treated for ocular hypertension and glaucoma. |
| Q35590150 | Psychophysical characterisation of early functional loss in glaucoma and ocular hypertension |
| Q44544119 | Pulmonary hypertension revealed by bilateral venous occlusion associated with ocular hypertension |
| Q33758607 | Quantification of retinal nerve fiber layer thickness in normal eyes, eyes with ocular hypertension, and glaucomatous eyes with SD-OCT. |
| Q99350187 | Rac1 conditional deletion attenuates retinal ganglion cell apoptosis by accelerating autophagic flux in a mouse model of chronic ocular hypertension |
| Q33196738 | Racial differences in optic disc topography: baseline results from the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study |
| Q78206572 | Random dot motion stimuli are more sensitive than light stimuli for detection of visual field loss in ocular hypertension patients |
| Q57197704 | Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension |
| Q44497029 | Randomized clinical trial comparing intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma |
| Q34737217 | Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension |
| Q91632338 | Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma |
| Q100523466 | Randomized, double-masked trial of netarsudil 0.02% ophthalmic solution for prevention of corticosteroid-induced ocular hypertension |
| Q35589405 | Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma |
| Q67747695 | Rate and Pattern of Neuroretinal Rim Area Decrease in Ocular Hypertension and Glaucoma |
| Q44674915 | Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma |
| Q38459922 | Rate of visual field progression in eyes with optic disc hemorrhages in the ocular hypertension treatment study |
| Q74593687 | Re: Central corneal thickness, tonometry, and ocular dimensions in glaucoma and ocular hypertension |
| Q88125107 | Re: Fast circulation of cerebrospinal fluid: an alternative perspective on the protective role of high intracranial pressure in ocular hypertension |
| Q101563316 | Re: Kaba et al.: The effectiveness and safety of micropulse cyclophotocoagulation in the treatment of ocular hypertension and glaucoma (Ophthalmology Glaucoma. 2020;3:181-189) |
| Q35099312 | Reasons for early ocular hypertension after uneventful cataract surgery |
| Q40650840 | Recurrent corneal edema without ocular hypertension, pigment degeneration combined with deafness, progressive dystrophy of the outer eye-muscles in a patient with proportional dwarfism and diabetes mellitus (author's transl) |
| Q84113079 | Reduced endothelial progenitor cells and brachial artery flow-mediated dilation as evidence of endothelial dysfunction in ocular hypertension and primary open-angle glaucoma |
| Q78094381 | Reduced plasma cortisol binding to albumin in ocular hypertension and primary open-angle glaucoma |
| Q36185997 | Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study |
| Q42652830 | Referral source, symptoms, and severity at diagnosis of ocular hypertension or open-angle glaucoma in various practices |
| Q44978218 | Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide |
| Q46803018 | Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection |
| Q36387437 | Relationship between Elevated Intraocular Pressure and Divided Peripapillary Sector Retinal Nerve Fiber Layer Thickness in a Cynomolgus Monkey Laser-Induced Ocular Hypertension Model |
| Q42545442 | Relationship between caffeine-induced ocular hypertension and ultrastructure changes of non-pigmented ciliary epithelial cells in rats |
| Q33263482 | Relationship between central corneal thickness and changes of optic nerve head topography and blood flow after intraocular pressure reduction in open-angle glaucoma and ocular hypertension |
| Q95262226 | Relationship between intraocular pressure and parameters of obesity in ocular hypertension |
| Q92948822 | Relationship between intraocular pressure and retinal nerve fibre thickness loss in a monkey model of chronic ocular hypertension |
| Q79467746 | Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma |
| Q33492376 | Relationships between central corneal thickness and optic disc topography in eyes with glaucoma, suspicion of glaucoma, or ocular hypertension |
| Q38123700 | Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials |
| Q67791896 | Relevance of ocular pressure tonometry and classical tonometry with reference to prognosis in suspected glaucoma and ocular hypertension |
| Q34230259 | Remarks on the Artificial Induction of Ocular Hypertension by Compression of the Jugular Veins. |
| Q87096694 | Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma |
| Q81271273 | Reproducibility of self-measured intraocular pressure with the phosphene tonometer in patients with ocular hypertension and early to advanced glaucoma |
| Q92831353 | Republished: Severe acute ocular hypertension following pulsed methylprednisolone for juvenile idiopathic arthritis |
| Q34301418 | Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. |
| Q42618809 | Response variability in the visual field: comparison of optic neuritis, glaucoma, ocular hypertension, and normal eyes. |
| Q33324423 | Results of the ocular hypertension treatment study and the confocal scanning laser ophthalmoscopy ancillary study and evaluation of the heidelberg retina tomograph |
| Q89078228 | Resveratrol ameliorates disorders of mitochondrial biogenesis and dynamics in a rat chronic ocular hypertension model |
| Q33681832 | Retinal Ganglion Cell Loss in a Rat Ocular Hypertension Model Is Sectorial and Involves Early Optic Nerve Axon Loss |
| Q69659962 | Retinal nerve fiber layer and neuroretinal rim changes in ocular hypertension and early glaucoma |
| Q86144118 | Retinal neurovascular coupling in patients with glaucoma and ocular hypertension and its association with the level of glaucomatous damage |
| Q31095392 | Retinal thickness at the posterior pole in glaucoma and ocular hypertension |
| Q71493324 | Retinal vascular accidents in glaucoma and ocular hypertension |
| Q70624128 | Retinal vein occlusion and ocular hypertension |
| Q70390640 | Retinal, choroidal, and papillary circulations under conditions of induced ocular hypertension |
| Q84917727 | Reversal of optic disc cupping and pallor in patients with ocular hypertension using timolol therapy |
| Q35873228 | Review of the ischemia hypothesis for ocular hypertension other than congenital glaucoma and closed-angle glaucoma |
| Q90211892 | Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension |
| Q35008515 | RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork |
| Q89084647 | Risk Factors and the Incidence of Ocular Hypertension After Penetrating Keratoplasty |
| Q91434922 | Risk Factors for the Development of Ocular Hypertension After Keratoplasty: A Systematic Review |
| Q61631250 | Risk Factors to Develop Ocular Surface Disease in Treated Glaucoma or Ocular Hypertension Patients |
| Q38083512 | Risk factors and incidence of ocular hypertension after penetrating keratoplasty |
| Q98463603 | Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema |
| Q85749676 | Risk factors for ocular hypertension after penetrating keratoplasty |
| Q54037200 | Risk factors of ocular hypertension and glaucoma. The Casteldaccia Eye Study. |
| Q36347352 | Risk factors predicting steroid-induced ocular hypertension after photorefractive keratectomy. |
| Q36354205 | Risk of Ocular Hypertension in Adults with Noninfectious Uveitis |
| Q44910760 | Risk of glaucoma in ocular hypertension with and without pseudoexfoliation |
| Q42665102 | Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids |
| Q34394275 | Rod-like microglia are restricted to eyes with laser-induced ocular hypertension but absent from the microglial changes in the contralateral untreated eye. |
| Q64107650 | Role of Histamine H₃ Receptor Antagonists on Intraocular Pressure Reduction in Rabbit Models of Transient Ocular Hypertension and Glaucoma |
| Q36440512 | Role of Nd:YAG peripheral iridectomy in the management of ocular hypertension with a narrow angle |
| Q91885646 | Role of Pattern Electroretinogram in Ocular Hypertension and Early Glaucoma |
| Q43947680 | Role of dopaminergic receptors in glaucomatous disease modulation |
| Q42943389 | Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides |
| Q71493338 | Roundtable discussion. Management of ocular hypertension |
| Q45040649 | S-cone, L + M-cone, and pattern, electroretinograms in ocular hypertension and glaucoma |
| Q35958006 | SELECTIVE LASER TRABECULOPLASTY--SHORT TERM EFFICACY AND SAFETY PROFILE IN OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION TREATMENT. |
| Q77224308 | STUDY OF THE ACTION OF 3 SYMPATOMIMETIC AMINES ON EXPERIMENTAL OCULAR HYPERTENSION IN THE RABBIT |
| Q36162811 | Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma |
| Q90897918 | Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study |
| Q95559465 | Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension |
| Q95384145 | Safety and efficacy of combined trabeculectomy for primary angle closure glaucoma with persistent ocular hypertension |
| Q34090075 | Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy |
| Q97529802 | Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study |
| Q30662061 | Scanning laser ophthalmoscopy of the optic nerve head in exfoliation glaucoma and ocular hypertension with exfoliation syndrome |
| Q36745634 | Seasonal changes in visual field sensitivity and intraocular pressure in the ocular hypertension treatment study. |
| Q91483368 | Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice |
| Q37132686 | Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors |
| Q37775031 | Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion. |
| Q98464375 | Secondary ocular hypertension post intravitreal dexamethasone implant (OZURDEX) managed by pars plana implant removal along with trabeculectomy in a young patient |
| Q70378573 | Selective Perimetry for Glaucomatous Defects in Ocular Hypertension |
| Q96175080 | Selective laser trabeculoplasty (SLT) performed by optometrists for patients with glaucoma and ocular hypertension: a scoping review protocol |
| Q91546121 | Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT |
| Q64117413 | Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial |
| Q69720746 | Sensory nerve responses elicited by experimental ocular hypertension |
| Q36683623 | Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study |
| Q37434479 | Severe Corticosteroid-Induced Ocular Hypertension Requiring Bilateral Trabeculectomies in a Patient with Takayasu's Arteritis |
| Q64994109 | Severe acute ocular hypertension following pulsed methylprednisolone for juvenile idiopathic arthritis. |
| Q36333381 | Severe ocular hypertension secondary to systemic corticosteroid treatment in a child with nephrotic syndrome |
| Q35886798 | Shared care of patients with ocular hypertension in the Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES). |
| Q91575101 | Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension |
| Q95820921 | Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension |
| Q33205294 | Short-term effect of latanoprost on ocular circulation in ocular hypertension |
| Q79301619 | Short-term effects of latanoprost on anterior chamber depth in patients with glaucoma or ocular hypertension |
| Q104744540 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis |
| Q44787259 | Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects |
| Q43239422 | Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlle |
| Q64280813 | Silicone oil-induced ocular hypertension and glaucomatous neurodegeneration in mouse |
| Q42618225 | Simultaneous comparison of relative damage to chromatic pathways in ocular hypertension and glaucoma: correlation with clinical measures |
| Q72188547 | Simultaneous interocular brightness sense testing in ocular hypertension and glaucoma |
| Q44530545 | Six-month randomized clinical trial comparing intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma |
| Q40234109 | Six-year incidence of ocular hypertension in a South Indian population: the Chennai eye disease incidence study |
| Q30660821 | Slope analysis of the optic disc in eyes with ocular hypertension and early normal tension glaucoma by confocal scanning laser ophthalmoscope |
| Q37494344 | Smad3 is necessary for transforming growth factor-beta2 induced ocular hypertension in mice |
| Q70763907 | Solitary silent venous papillary loops and ocular hypertension |
| Q66919277 | Some current thoughts on ocular hypertension |
| Q71478510 | Specific deficits of flicker sensitivity in glaucoma and ocular hypertension |
| Q45005163 | Spectrometric investigations in ocular hypertension and early stages of primary open angle glaucoma and of low tension glaucoma--multisubstance analysis |
| Q84618949 | Spontaneous hyphaema and acute ocular hypertension associated with severe lens-induced uveitis |
| Q71131463 | Spontaneous trends in ocular pressure in untreated ocular hypertension |
| Q34612319 | Standard automated perimetry versus matrix frequency doubling technology perimetry in subjects with ocular hypertension and healthy control subjects |
| Q35838670 | Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial |
| Q35870341 | Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension |
| Q68090872 | Steroid glaucoma: corticosteroid-induced ocular hypertension in cats |
| Q36659472 | Steroid induced ocular hypertension following myopic photorefractive keratectomy |
| Q87952943 | Steroid-induced ocular hypertension after photorefractive keratectomy |
| Q36173241 | Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis |
| Q54483515 | Steroid-induced ocular hypertension in high myopia. |
| Q45101409 | Steroid-induced ocular hypertension in normal cattle |
| Q46340395 | Steroid-induced ocular hypertension in normal sheep |
| Q41646390 | Steroid-induced ocular hypertension in patients with filtering blebs. |
| Q53700298 | Steroid-induced ocular hypertension in the pediatric age group. |
| Q42277136 | Steroid-induced ocular hypertension in the presence of a functioning Molteno seton |
| Q68842423 | Steroid-induced ocular hypertension in the rabbit: a model using subconjunctival injections |
| Q50537908 | Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report. |
| Q89294020 | Steroid-induced protracted severe ocular hypertension in a 14-year-old girl |
| Q89805277 | Structural Changes and Astrocyte Response of the Lateral Geniculate Nucleus in a Ferret Model of Ocular Hypertension |
| Q44186859 | Structural glaucomatous damage vs. visual field defects: longitudinal study in patients with ocular hypertension or early primary open-angle glaucoma. |
| Q46666563 | Structure-function relationship in ocular hypertension and glaucoma: interindividual and interocular analysis by OCT and pattern ERG. |
| Q33263191 | Study of patients with ocular hypertension with scanning laser polarimetry and short-wavelength automatic perimetry. |
| Q39942496 | Subtenon Triamcinolone Acetonide Removal for Uncontrolled Ocular Hypertension After Posterior Subtenon Injection of Triamcinolone Acetonide |
| Q43138131 | Suppression and reduction of corticosteroid-induced ocular hypertension by anecortave in sheep |
| Q43138135 | Suppression of corticosteroid-induced ocular hypertension in sheep by anecortave |
| Q53836879 | Surgical effect on combined forms of ocular hypertension in narrow-angle glaucoma |
| Q45344065 | Surgical intervention of steroid-induced ocular hypertension from Ozurdex |
| Q26864292 | Surveillance for ocular hypertension: an evidence synthesis and economic evaluation |
| Q33911475 | Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab |
| Q30534999 | Sustained ocular hypertension induces dendritic degeneration of mouse retinal ganglion cells that depends on cell type and location |
| Q45929500 | Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. |
| Q43883442 | Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model |
| Q44919993 | Symmetry analysis for detecting early glaucomatous changes in ocular hypertension using optical coherence tomography |
| Q69470775 | Sympathetic denervation hypersensitivity of the iris in ocular hypertension |
| Q33403214 | Synaptic degeneration of retinal ganglion cells in a rat ocular hypertension glaucoma model |
| Q51822834 | Systemic PTEN-Akt1-mTOR pathway activity in patients with normal tension glaucoma and ocular hypertension: A case series. |
| Q42142426 | TGF-β(1) in retinal ganglion cells in rats with chronic ocular hypertension: its expression and anti-apoptotic effect |
| Q33835663 | TGF-β2-mediated ocular hypertension is attenuated in SPARC-null mice |
| Q88011910 | TOLERANCE OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA |
| Q77148433 | TRANSITIONAL OCULAR HYPERTENSION IN THE USE OF CORTICOSTEROIDS |
| Q60369038 | The 10-Year Incidence of Glaucoma Among Patients With Treated and Untreated Ocular Hypertension |
| Q72335663 | The Bjerrum area in ocular hypertension |
| Q97906234 | The Dynamic Scleral Extracellular Matrix Alterations in Chronic Ocular Hypertension Model of Rats |
| Q97545304 | The Effectiveness and Safety of Micropulse Cyclophotocoagulation in the Treatment of Ocular Hypertension and Glaucoma |
| Q85456094 | The Effects of Fixed Combination of Bimatoprost-Timolol and Travoprost-Timolol on Intraocular Pressure in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension, Previously on Nonfixed Combination of Latanoprost and Timolol |
| Q89242784 | The Epidemiology of Medical Treatment for Glaucoma and Ocular Hypertension in Germany |
| Q95796962 | The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results? |
| Q33252696 | The French glaucoma and ocular hypertension 1-day study |
| Q91580589 | The Genetic Influence on Corticosteroid-Induced Ocular Hypertension: A Field Positioned for Discovery |
| Q72752276 | The Heritable Nature of Dexamethasone-Induced Ocular Hypertension |
| Q58003979 | The Impact of Physician Subspecialty Training, Risk Calculation, and Patient Age on Treatment Recommendations in Ocular Hypertension |
| Q103003772 | The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma |
| Q47225888 | The Microbead Occlusion Model of Ocular Hypertension in Mice. |
| Q92034885 | The Molecular Processes in the Trabecular Meshwork After Exposure to Corticosteroids and in Corticosteroid-Induced Ocular Hypertension |
| Q53872479 | The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. |
| Q42677806 | The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. |
| Q44288112 | The Ocular Hypertension Treatment Study: design and baseline description of the participants |
| Q52936303 | The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. |
| Q80200368 | The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals |
| Q90621707 | The Relationship Between Scleral Strain Change and Differential Cumulative Intraocular Pressure Exposure in the Nonhuman Primate Chronic Ocular Hypertension Model |
| Q47737232 | The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma |
| Q38637048 | The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies |
| Q28273961 | The Utility of Diaton Tonometer Measurements in Patients With Ocular Hypertension, Glaucoma, and Glaucoma Tube Shunts: A Preliminary Study for its Potential Use in Keratoprosthesis Patients |
| Q71964915 | The action of aceclydine in ocular hypertension |
| Q58597243 | The assessment of structural changes on optic nerve head and macula in primary open angle glaucoma and ocular hypertension |
| Q36463819 | The assisted-diagnosis by identification program, an expert system for acquired ocular hypertension in adults |
| Q46232107 | The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study |
| Q40299387 | The association of ocular hypertension with the exfoliation syndrome, the pigmentary dispersion syndrome and myopia |
| Q81446100 | The association of office intraocular pressure fluctuation in ocular hypertension with frequency doubling technology perimetry abnormality |
| Q70673627 | The changes in the blood supply of the posterior pole of rabbits with ocular hypertension |
| Q31037908 | The clinical analysis of corticosteroid ocular hypertension and corticosteroid glaucoma after photorefractive keratectomy |
| Q72538431 | The comparative multiple-dose intraocular pressure responses of nadolol and timolol in glaucoma and ocular hypertension |
| Q33198261 | The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors |
| Q69197290 | The cup-disc ratio and ocular hypertension |
| Q33214198 | The economic burden of glaucoma and ocular hypertension: implications for patient management: a review |
| Q31151327 | The effect of AQP4 knock out on retinal electrophysiology in laser-induced ocular hypertension mice |
| Q36710505 | The effect of acute and persistent ocular hypertension on ultrastructure in rabbit tissues of anterior chamber angle |
| Q30844126 | The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension |
| Q30829433 | The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected] |
| Q34433542 | The effect of changes in intraocular pressure on the risk of primary open-angle glaucoma in patients with ocular hypertension: an application of latent class analysis |
| Q71415526 | The effect of d-timolol on intraocular pressure in patients with ocular hypertension |
| Q38580900 | The effect of flavonoids on visual function in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. |
| Q85475577 | The effect of latanoprost and influence of changes in body position on patients with glaucoma and ocular hypertension |
| Q47701277 | The effect of ocular hypertension caused by red cells on the rate of formation of aqueous humor |
| Q36443452 | The effect of phacoemulsification surgery on intraocular pressure and anterior segment anatomy of the patients with cataract and ocular hypertension |
| Q31159298 | The effect of puncture actions on the ocular hypertension caused by chronic stimulation of the hypothalamus and amygdaloid body |
| Q34293508 | The effect of selective laser trabeculoplasty on aqueous humor dynamics in patients with ocular hypertension and primary open-angle glaucoma. |
| Q46145172 | The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading |
| Q77211569 | The effect of topical diltiazem on ocular hypertension induced by water loading in rabbits |
| Q41719233 | The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group |
| Q68852221 | The effects of experimental ocular hypertension on the electroretinogram and ultrastructure of the retina in rabbits |
| Q33255524 | The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension |
| Q47613762 | The effects of visual field changes and ocular hypertension on the visual evoked potential |
| Q79453393 | The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma |
| Q89919125 | The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis |
| Q35761955 | The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. |
| Q100760415 | The evaluation of juvenile ocular hypertension by optical coherence tomography angiography |
| Q33924046 | The expression patterns of Nogo-A, myelin associated glycoprotein and oligodendrocyte myelin glycoprotein in the retina after ocular hypertension: the expression of myelin proteins in the retina in glaucoma |
| Q69470977 | The hypotensive effect of verapamil eye drops on ocular hypertension |
| Q89741992 | The impact of intraocular pressure fluctuations and other factors on conversion of ocular hypertension to primary open-angle glaucoma |
| Q34795992 | The incidence of retinal vein occlusion in the ocular hypertension treatment study |
| Q83734123 | The influence of disease severity on quality of eye-drop administration in patients with glaucoma or ocular hypertension |
| Q41990663 | The laser in glaucoma and ocular hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics |
| Q57487878 | The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension |
| Q84917710 | The malmo high risk ocular hypertension study |
| Q45153010 | The mechanism of the antagonism of experimentally induced ocular hypertension by polyphloretin phosphate |
| Q33847407 | The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice |
| Q71153898 | The mode of progressive disc cupping in ocular hypertension and glaucoma |
| Q70658407 | The natural course of ocular pressure in ocular hypertension |
| Q43586937 | The natural history of glaucoma and ocular hypertension after pediatric cataract surgery |
| Q48255040 | The occurrence of delayed ocular hypertension and glaucoma after pars plana vitrectomy for rhegmatogenous retinal detachment. |
| Q70284996 | The occurrence of senile cataracts, ocular hypertension and glaucoma in rhesus monkeys |
| Q84918025 | The ocular hypertension treatment study |
| Q35684913 | The ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease? |
| Q52561005 | The pattern electroretinogram (PERG) in ocular hypertension and glaucoma. |
| Q44128542 | The pattern electroretinogram in early glaucoma and ocular hypertension |
| Q71356967 | The pressure lowering effect of ascorbic acid in ocular hypertension |
| Q43825983 | The prevalence and implications of ocular hypertension and glaucoma in thyroid-associated orbitopathy |
| Q43600442 | The prevalence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus. An epidemiological study of diabetes mellitus on the island of Falster, Denmark |
| Q70420243 | The prevalence of ocular hypertension in patients of an optometrist and the incidence of glaucoma occurring during long-term follow-up of ocular hypertensives |
| Q36599910 | The probability of glaucoma from ocular hypertension determined by ophthalmologists in comparison to a risk calculator. |
| Q68582287 | The progress of the visual field in chronic simple glaucoma and ocular hypertension treated topically with pilocarpine or with timolol |
| Q34623809 | The rate of structural change: the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study |
| Q35797177 | The rate of visual field change in the ocular hypertension treatment study. |
| Q33272527 | The response of retrobulbar vasculature to hypercapnia in primary open-angle glaucoma and ocular hypertension |
| Q34680468 | The role of confocal scanning laser ophthalmoscopy in stereometric differentiation of eye papilla in ocular hypertension, normal tension glaucoma and primary open-angle glaucoma |
| Q85055814 | The role of pachymetry in primary care as a refinement tool of ocular hypertension and glaucoma referrals |
| Q86628487 | The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension |
| Q33435399 | The selective vulnerability of retinal ganglion cells in rat chronic ocular hypertension model at early phase. |
| Q46155725 | The temporal visuogram in ocular hypertension and its progression to glaucoma. |
| Q34005853 | The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. |
| Q77733358 | The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension |
| Q34565377 | The usefulness of a new method of testing for a relative afferent pupillary defect in patients with ocular hypertension and glaucoma. |
| Q33629617 | The utility of the monocular trial: data from the ocular hypertension treatment study |
| Q70900644 | The value of osmotic hypotonising means for the treatment of ocular hypertension |
| Q33287406 | The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy |
| Q47257700 | The visual evoked potential in glaucoma and ocular hypertension: effects of check size, field size, and stimulation rate. |
| Q42643935 | The visual field in chronic simple glaucoma and ocular hypertension; its character, progress, relationship to the level of intraocular pressure and response to treatment |
| Q68057892 | Therapeutic problems in ocular hypertension |
| Q70805090 | Therapeutic problems in ocular hypertension |
| Q38796640 | Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study |
| Q43875360 | Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering |
| Q58699191 | Time Course Changes of the Mechanical Properties of the Iris Pigment Epithelium in a Rat Chronic Ocular Hypertension Model |
| Q33197017 | Time-specific intraocular pressure curves in Rhesus macaques (Macaca mulatta) with laser-induced ocular hypertension |
| Q87742215 | Timolol 0.1% gel versus timolol 0.5% eyedrops in the prophylaxis of ocular hypertension after phacoemulsification surgery |
| Q73901096 | Timolol gel versus acetazolamide in the prophylaxis of ocular hypertension after phacoemulsification |
| Q71025473 | Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma |
| Q42007617 | Timolol in maintenance treatment of ocular hypertension and glaucoma |
| Q34164333 | Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial. |
| Q59698052 | Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension |
| Q36134942 | Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study |
| Q104694089 | Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study |
| Q74821961 | Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber |
| Q35990935 | Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study |
| Q72810701 | Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension |
| Q79311200 | Topical therapies for glaucoma and ocular hypertension: an update on current practice |
| Q51551264 | Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma or ocular hypertension: Long-term results. |
| Q44874373 | Trabeculectomy and postoperative ocular hypertension in secondary angle-closure glaucoma |
| Q41966541 | Tracking longitudinal retinal changes in experimental ocular hypertension using the cSLO and spectral domain-OCT. |
| Q92581257 | Transduction Pattern of AAVs in the Trabecular Meshwork and Anterior-Segment Structures in a Rat Model of Ocular Hypertension |
| Q41544420 | Transient ocular hypertension following trabeculectomy |
| Q71930831 | Transiently raised intraocular pressure reveals pattern electroretinogram losses in ocular hypertension |
| Q34439271 | Transorbital superior ophthalmic vein sacrifice to preserve vision in ocular hypertension from aseptic cavernous sinus thrombosis |
| Q85895193 | Transorbital superior ophthalmic vein sacrifice to preserve vision in ocular hypertension from aseptic cavernous sinus thrombosis |
| Q78052771 | Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension |
| Q42602131 | Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials |
| Q37236653 | Travoprost in the management of open-angle glaucoma and ocular hypertension |
| Q93634929 | Treating ocular hypertension and glaucoma pays off |
| Q36514147 | Treating ocular hypertension to reduce glaucoma risk: when to treat? |
| Q91106428 | Treatment choices for newly diagnosed primary open angle and ocular hypertension patients |
| Q72587401 | Treatment of Ocular Hypertension and Glaucoma with Dopamine Antagonists |
| Q89771827 | Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study |
| Q91332577 | Treatment of canine postoperative ocular hypertension with combined latanoprost 0.005% and atropine 1% ophthalmic solutions |
| Q92785368 | Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595 |
| Q78098216 | Treatment of ocular hypertension and glaucoma with modified xiaoyao san (ease powder) |
| Q30789570 | Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials |
| Q73840749 | Treatment of ocular hypertension by adrenalin and diverse sympathomimetic amines |
| Q68941171 | Treatment of ocular hypertension with oral beta-adrenergic blocking agents |
| Q83155268 | Treatment of ocular hypertension: Hamlet's Lament revisited |
| Q35841772 | Treatment of ocular hypertension: is it cost effective? |
| Q33938212 | Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus |
| Q33253994 | Triamcinolone acetonide-induced ocular hypertension |
| Q71056853 | Trophic changes in the anterior uvea in the diagnosis of glaucoma and ocular hypertension |
| Q86814488 | Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension |
| Q34565322 | Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. |
| Q87449520 | Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension |
| Q101227375 | Two-Year Multicenter Outcomes of iStent inject Trabecular Micro-Bypass Stents Combined with Phacoemulsification in Various Types of Glaucoma and Ocular Hypertension |
| Q33395629 | Two-year outcomes of selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension |
| Q30486111 | UBM/slit-lamp-photo imaging of pseudoexfoliation deposits in the iridocorneal angle: imaging clues to the genesis of ocular hypertension |
| Q37126878 | Ultrasound biomicroscopic evaluation of anterior segment cysts as a risk factor for ocular hypertension and closure angle glaucoma |
| Q34020747 | Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice. |
| Q43595162 | Undergoing retinal detachment and primitive ocular hypertension (author's transl) |
| Q71110683 | Unilateral pseudo-exfoliation, ocular hypertension and the cup disc ratio |
| Q28576585 | Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension |
| Q43119198 | Up-regulation of crystallins is involved in the neuroprotective effect of wolfberry on survival of retinal ganglion cells in rat ocular hypertension model |
| Q54124212 | Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. |
| Q33208449 | Use of corneal pachymetry in ocular hypertension and chronic glaucoma |
| Q30857811 | Use of data display screens and ocular hypertension in local public sector workers |
| Q44275543 | Using the arteriolar Pressure Attenuation Index to predict ocular hypertension progression to open-angle glaucoma |
| Q89705257 | Uveitic Ocular Hypertension and Glaucoma |
| Q96347584 | Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma |
| Q34734517 | Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma |
| Q64251077 | Vagal Nerve Stimulation Attenuates Ischemia-Reperfusion Induced Retina Dysfunction in Acute Ocular Hypertension |
| Q36016893 | Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension |
| Q46304274 | Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma |
| Q37467434 | Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study |
| Q101241093 | Venous stasis retinopathy in a ten-year-old boy with ocular hypertension: a case report |
| Q94661663 | Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial |
| Q48332800 | Visual evoked cortical potential to paracentral retinal stimulation in chronic glaucoma, ocular hypertension, and an age-matched group of normals |
| Q42596479 | Visual evoked potentials in patients with Graves' ophthalmopathy complicated by ocular hypertension and suspect glaucoma or dysthyroid optic neuropathy |
| Q33619950 | Visual fatigue and visual evoked potentials in multiple sclerosis, glaucoma, ocular hypertension and Parkinson's disease |
| Q71418864 | Visual field defects in ocular hypertension and glaucoma |
| Q45937910 | Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). |
| Q44186847 | Visual field testing in patients with ocular hypertension and localized RNFL defects. |
| Q77958700 | Visual function correlates with nerve fiber layer thickness in eyes affected by ocular hypertension |
| Q34937595 | Visual-field loss with optic nerve drusen and ocular hypertension: a case report. |
| Q47811272 | Vulnerability study of myelinated and unmyelinated nerve fibers in acute ocular hypertension in rabbit |
| Q35684914 | We should treat fewer patients with elevated intraocular pressure now that we know the results of the ocular hypertension treatment study |
| Q33472189 | Weather influences on intraocular pressure in patients with chronic glaucoma or ocular hypertension |
| Q87947448 | What We Have Learned From the Ocular Hypertension Treatment Study |
| Q88667367 | What We Have Learned From the Ocular Hypertension Treatment Study |
| Q71162008 | When to treat ocular hypertension |
| Q71177663 | When to treat ocular hypertension |
| Q85455933 | You're the flight surgeon: ocular hypertension |
| Q72961256 | [2 cases of traumatic cyclodialysis, followed by high temporary ocular hypertension, then complee recovery] |
| Q72084509 | [A case of acute ocular hypertension disclosing homocystinuria in an adult woman] |
| Q53878550 | [A comparison between latanoprost and timolol in treatment of patients with primary open-angle glaucoma and ocular hypertension] |
| Q54148636 | [A test of pressure tolerance of the optic nerve head in ocular hypertension] |
| Q95452660 | [Acupuncture at cervical Jiaji (EX-B 2) points for 60 cases of ocular hypertension] |
| Q69016435 | [Acute ocular hypertension] |
| Q74559110 | [An observation on calcium ion overloaded injury and the effect of calcium channel blocker in rabbit retina under acute ocular hypertension] |
| Q67267962 | [Anatomo-pathologic findings in ocular hypertension caused by retinal vascular lesions] |
| Q95789815 | [Antagonistic effect of local epinephrine and phenylephrine administration on ocular hypertension induced by perfusion of secondary autologous aqueous humor in the rabbit] |
| Q78396467 | [Apparently favorable effect of intercurrent ocular hypertension on the development of several cases of retinal detachment] |
| Q70359691 | [Assessment of the optic disk in ocular hypertension and glaucoma] |
| Q69630863 | [Asymmetry in eye position as 1 of the criteria for establishing the diagnosis of glaucoma and ocular hypertension] |
| Q68041904 | [Automated campimetry with video screen: analysis of 565 cases with ocular hypertension] |
| Q54146185 | [Basic differential diagnostic criteria of initial open-angle glaucoma and essential ocular hypertension] |
| Q74522618 | [Bilateral retinopathy with ocular hypertension in a young patient in a paradiabetic state] |
| Q73248368 | [Central corneal thickness in normal eyes, patients with ocular hypertension, normal-pressure and open-angle glaucomas--a clinical study] |
| Q80159782 | [Central thickness of the cornea in ocular hypertension and open-angle glaucoma] |
| Q54054772 | [Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension] |
| Q93143647 | [Clinical features of glucocorticoid eye drops induced ocular hypertension in pediatric and adult uveitic eyes] |
| Q53888104 | [Comment on Velten IM, Bergua A, Horm FK, Junemann A, Korth M. "Central corneal thickness in normal probands, patients with ocular hypertension, normal pressure and open-angle glaucomas--a clinical study"] |
| Q54130630 | [Comparative study of levobunolol and timolol in the treatment of chronic open-angle glaucoma and chronic ocular hypertension] |
| Q54033262 | [Comparison of 0.1% dipivalyl epinephrine and 1% epinephrine in patients with glaucoma or ocular hypertension] |
| Q85346477 | [Comparison of dynamic contour tonometry, Goldmann and pneumotonometer in ocular hypertension patients and their relationship to pachymetry and ocular pulse amplitude] |
| Q70254877 | [Comparison of the effectiveness and safety of levobunolol and timolol in ocular hypertension and chronic open-angle glaucoma] |
| Q88104982 | [Complement activation after induction of ocular hypertension in an animal model] |
| Q73288992 | [Complications of acute ocular hypertension in general surgery] |
| Q74448333 | [Congenital glaucoma with absence of megalocornea and late occurrence of ocular hypertension] |
| Q70047272 | [Contraindicated medications in ocular hypertension] |
| Q57102882 | [Contrast sensitivity in glaucoma and ocular hypertension] |
| Q46016616 | [Contribution and significance of Heidelberg Retinal Tomography II in diagnostics of ocular hypertension and its conversion into primary open-angle glaucoma]. |
| Q72914315 | [Contribution to the study of ocular hypertension caused by dexamethasone in open angle glaucoma] |
| Q82552365 | [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension] |
| Q53878541 | [Corneal thickness and intraocular pressure in cases with ocular hypertension and glaucoma] |
| Q95616029 | [Current therapeutic possibilities for uveal ocular hypertension] |
| Q70634198 | [Diabetes, ocular hypertension and glaucoma] |
| Q86739838 | [Diagnosis of a clear cell renal carcinoma by biopsy of an iris metastasis associated with ocular hypertension in a black man from Martinique: Case report and literature review] |
| Q71086465 | [Differential diagnosis of essential ocular hypertension and initial open-angle glaucoma] |
| Q70529696 | [Differential diagnosis of ocular hypertension] |
| Q83991203 | [Does the ocular hypertension need treatment] |
| Q84514865 | [Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension] |
| Q53111194 | [Effect of Morphological and Functional Parameters on Ocular Pulse Amplitudes: An Analysis in Ocular Hypertension and Different Types of Glaucoma]. |
| Q70745231 | [Effect of hypotensive agents on prostaglandin-induced ocular hypertension] |
| Q67242379 | [Effect of ocular hypertension on the optic nerve and the lamina cribrosa in cats] |
| Q70411510 | [Effect of ocular hypertension on the retinal vessels and tissues in the cat] |
| Q71049561 | [Effect of the level and duration of ocular hypertension on the changes in the optic disk] |
| Q54290081 | [Effect of the size of the disc cup on the area of the isopters in normal, ocular hypertension and glaucomatous eyes]. |
| Q83725561 | [Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension] |
| Q80342826 | [Effects of reading, exercise and exercise combined with reading on intraocular pressure for patients sustaining primary glaucoma (open angle) or ocular hypertension, both clinically controlled with topic medication] |
| Q53855298 | [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension] |
| Q70916332 | [Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension] |
| Q85619099 | [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension] |
| Q80052106 | [Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension] |
| Q53680889 | [Episcleral venous pressure in primary glaucoma, ocular hypertension and in patients with hypertension] |
| Q70669810 | [Essential ocular hypertension and the initial onset of open-angle glaucoma] |
| Q83079810 | [Evaluation of the Ocular Response Analyzer in ocular hypertension, glaucoma, and normal populations. Prospective study on 329 eyes] |
| Q72506960 | [Experimental studies on changes in retinal enzyme activities under acute ocular hypertension in cat eyes] |
| Q73369097 | [Experimental study on ocular hypertension] |
| Q83960097 | [Expression of glucocorticoid receptors alpha and beta in mononuclear cells of peripheral blood in patients with glucocorticoid-induced ocular hypertension] |
| Q73205301 | [Factors influencing early post surgical ocular hypertension after phacoemulsification] |
| Q83865828 | [First experience with the Heidelberg Edge Perimeter® on patients with ocular hypertension and preperimetric glaucoma] |
| Q71208873 | [Fluorescein angiography of the papilla in ocular hypertension and glaucoma] |
| Q72386827 | [Free radical retinal damage in rabbits of experimental acute ocular hypertension] |
| Q74042490 | [Glaucoma and ocular hypertension in primary care] |
| Q70555303 | [Glaucoma and ocular hypertension: differential diagnosis] |
| Q71086497 | [Glaucoma and ocular hypertension: discriminant analysis of a group of diagnostic signs] |
| Q54142724 | [Glaucoma and ocular hypertension: study of homeostatic mechanisms] |
| Q53852238 | [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France] |
| Q53994292 | [Glaucoma and risk factors. Comparative study of cardiovascular risk factors in primary open-angle glaucoma, normal-pressure glaucoma and simple ocular hypertension] |
| Q73386247 | [Homatropine and ocular hypertension] |
| Q73585915 | [Hypertensive states of the eye; syndrome of ocular hypertension] |
| Q70786909 | [Hypotensive effects of intravenous glycerol in experimental ocular hypertension induced by triethyltin in the rabbit] |
| Q69439474 | [Incidence of ocular hypertension in melanoma of the eye] |
| Q74150241 | [Indications of various medical and surgical treatments and results of their mechanism of action in ocular hypertension] |
| Q70603107 | [Indices of ocular hemodynamics in patients with essential ocular hypertension] |
| Q70488224 | [Induced ocular hypertension: experimental investigations on rabbit eyes] |
| Q71574338 | [Influence of experimental ocular hypertension and reduction of the systemic blood pressure on circulation of posterior eye (author's transl)] |
| Q74270150 | [Initial findings with pulsar perimetry in patients with ocular hypertension] |
| Q70786883 | [Intravenous use of glycerol combined with sodium ascorbate or glucose in the treatment of cerebral edema and ocular hypertension in the rabbit] |
| Q79106467 | [Late ocular hypertension after severe contusion of the eyeball. Surgical problem.] |
| Q71557461 | [Long-term follow-up of ocular hypertension (report of 20 cases) (author's transl)] |
| Q91627746 | [MIGS-off-label option for treatment-refractory steroid-induced ocular hypertension] |
| Q84924636 | [Management of juvenile ocular hypertension] |
| Q80051771 | [Management of ocular hypertension and chronic open-angle glaucoma by French ophthalmologists: the role of target intraocular pressure] |
| Q54143920 | [Microcirculation and hemodynamics in ocular hypertension and open-angle glaucoma] |
| Q91134331 | [Modern view on ocular hypertension] |
| Q83306110 | [Morphology, family history, and age at diagnosis of 26 patients with Axenfeld-Rieger syndrome and glaucoma or ocular hypertension] |
| Q52408666 | [Nomogram for ocular hypertension progression risk based on the ocular hypertension treatment study] |
| Q73579226 | [Non-perforating retrociliary diathermy in the treatment of ocular hypertension] |
| Q74079360 | [Nyctohemeral variations of the effect of antithyroids on the level of organic and mineral ions of serum in chronic ocular hypertension] |
| Q82757410 | [Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment] |
| Q71471484 | [Ocular hypertension - corneal endothelium aspects in scanning electron microscopy] |
| Q68069814 | [Ocular hypertension after cataract surgery (intra- and extra-capsular)] |
| Q71129772 | [Ocular hypertension after intra-capsular cataract extraction] |
| Q87610689 | [Ocular hypertension after intravitreal injection, foreword] |
| Q89473654 | [Ocular hypertension after intravitreal injection: Screening and management] |
| Q86171259 | [Ocular hypertension after surgery for retinal detachment] |
| Q93522900 | [Ocular hypertension and glaucoma: 2 clinical entities?] |
| Q74771068 | [Ocular hypertension and glaucoma: the contribution of large studies to daily practice] |
| Q74382886 | [Ocular hypertension and thermal treatment at Vichy] |
| Q73298211 | [Ocular hypertension and uveitis. Study of 374 cases of uveitis] |
| Q81364512 | [Ocular hypertension as the principal indicator of onset of uveal melanoma] |
| Q70424893 | [Ocular hypertension caused by wearing soft lenses] |
| Q68680728 | [Ocular hypertension following local prostaglandin and changes of enzymatic activity in trabecular meshwork and ciliary epithelium (author's transl)] |
| Q83008067 | [Ocular hypertension in children treated with brimonidine 0.2%. A clinical study] |
| Q70269766 | [Ocular hypertension in endocrine ophthalmopathy] |
| Q72443903 | [Ocular hypertension in general halothane anesthesia] |
| Q95624005 | [Ocular hypertension in herpes simplex keratouveitis] |
| Q68638155 | [Ocular hypertension in patients with infiltrative-edematous exophthalmos in Graves' disease] |
| Q78831936 | [Ocular hypertension in the Weil-Marchesani syndrome.] |
| Q71361376 | [Ocular hypertension or glaucoma? (author's transl)] |
| Q87494135 | [Ocular hypertension secondary to iridocorneal angle metastasis of an anaplastic bronchial carcinoma] |
| Q73456327 | [Ocular hypertension, a symptom and not a disease] |
| Q70258899 | [Ocular hypertension, suspected glaucoma, preglaucoma or glaucoma? The points of view of scientists] |
| Q70242037 | [Ocular hypertension: results of a 10-year follow-up study] |
| Q80546931 | [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product] |
| Q53959056 | [Ocular pulse amplitude in ocular hypertension and open-angle glaucoma]. |
| Q79099024 | [On the treatment of secondary ocular hypertension after pupil seclusion.] |
| Q70563988 | [Optic disc measurements for cup depth with computerized image analysis in normal subjects and case of ocular hypertension and glaucoma] |
| Q76038703 | [Origin of ocular hypertension in primary glaucoma.] |
| Q69682412 | [Pallor of the optic papilla--an early sign of glaucoma. A clinical controlled study of optic disk pallor and papillar cupping in glaucoma simplex, ocular hypertension and normal eyes with the optic nerve head analyzer] |
| Q68069845 | [Papillo-retino-choroidal hemodynamics during experimental ocular hypertension in normal and glaucomatous subjects] |
| Q74136949 | [Pathogenesis and therapy of ocular hypertension in exophthalmos caused by arteriovenous aneurysm] |
| Q68376079 | [Pathogenesis and treatment of ocular hypertension in exophthalmos due to arteriovenous aneurysm] |
| Q71579852 | [Pathogenesis and treatment of ocular hypertension in the climacterium] |
| Q67864704 | [Pattern ERG in ocular hypertension and glaucoma. Effect of pattern size, contrast and retinal eccentricity] |
| Q69455968 | [Photographic study of retinal nerve fibers in glaucoma and ocular hypertension] |
| Q79314036 | [Practical measures. When ocular hypertension is unilateral] |
| Q69532272 | [Predicting the development of ocular hypertension after cataract extraction] |
| Q98305661 | [Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204)] |
| Q80920874 | [Prevalance of open angle glaucoma and ocular hypertension as a risk factor for primary open angle glaucoma in Wroclaw population. Wroclaw Epidemiology Study] |
| Q70577284 | [Prevalence and background of ocular hypertension and low tension glaucoma] |
| Q68545876 | [Progressive external ophthalmoplegia and its associations. A case with ocular hypertension, tapeto-retinal degeneration and cardiac alterations] |
| Q95359522 | [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)] |
| Q82537157 | [Recommendations for follow-up examinations in patients with ocular hypertension] |
| Q73575015 | [Reflex nature of ocular hypertension associated with roentgen-irradiation] |
| Q70351464 | [Remanent efficiency of timolol in ocular hypertension (author's transl)] |
| Q71031816 | [Residual effect of timoptol in ocular hypertension] |
| Q68702895 | [Results of laser iridotomy in acute ocular hypertension] |
| Q53859894 | [Results of the Ocular Hypertension Treatment Study (OHTS)] |
| Q54133140 | [Results of visual evoked potentials in ocular hypertension] |
| Q78643216 | [Retinal detachment & ocular hypertension; 3 case reports.] |
| Q74079309 | [Retinal detachment and ocular hypertension] |
| Q73075714 | [Retrociliary diathermy in therapy of ocular hypertension] |
| Q80051820 | [Risk calculator for developing glaucoma from ocular hypertension: beware of the risk of confusion] |
| Q71112626 | [Significance of asymmetry of various diagnostic signs in the differential diagnosis of incipient open-angle glaucoma and ocular hypertension] |
| Q71831271 | [So-called ocular hypertension and new signs of primary open-angle glaucoma] |
| Q91521691 | [Spatial contrast sensitivity in patients with primary open-angle glaucoma and ocular hypertension] |
| Q79268437 | [Standardized acupuncture therapy in patients with ocular hypertension or glaucoma--results of a prospective observation study] |
| Q84868894 | [Steroid induced ocular hypertension and glaucoma] |
| Q77657547 | [Suppressing effect of isoforskolin and forskolin on ocular hypertension in rabbits] |
| Q73031837 | [The aggravating effect of ACTH and cortisone on ocular hypertension] |
| Q70501315 | [The corneal endothelial cell of ocular hypertension] |
| Q73691226 | [The effect of a new diuretic, diamox, on pathological ocular hypertension] |
| Q53915942 | [The influence of 0.85% RS-timolol and 0.5% S-timolol on intraocular pressure and systemic arterial blood pressure, heart rate, ECG, expiratory capacity in patients with ocular hypertension and primary open-angle glaucoma] |
| Q71605823 | [The influence of acute ocular hypertension on the ultrastructure of the rabbit retina--experimental glaucoma. Part II (author's transl)] |
| Q70916364 | [Treatment of ocular hypertension after trabeculectomy] |
| Q74288324 | [Treatment of ocular hypertension by induced ischemia of the ciliary body] |
| Q79398966 | [Treatment of ocular hypertension by ischemia of the ciliary body.] |
| Q74448360 | [Treatment of ocular hypertension by ligation of anterior ciliary arteries and electrocoagulation at the pathway of the long posterior ciliary arteries] |
| Q73873092 | [Treatment of ocular hypertension by reduction of aqueous humor outflow] |
| Q74014452 | [Treatment of ocular hypertension by the reduction of pressure in aqueous humor] |
| Q68012107 | [Treatment of ocular hypertension with ultrasonics (Sonocare). Preliminary results] |
| Q83958899 | [Triamcinolone induced ocular hypertension] |
| Q53798643 | [True tolerant intraocular pressure in glaucoma, ocular hypertension and low-tension glaucoma] |
| Q82368987 | [Two cases of juvenile ocular hypertension; verification and comparison tonometers; total peripheral visual field] |
| Q76236428 | [Two cases of ocular hypertension after oophorohysterectomy] |
| Q71254962 | [Two cases of retinal detachment with ocular hypertension and many outer segments of visual cells in the anterior chamber (author's transl)] |
| Q71768176 | [Ultrasonic decompression of malignant ocular hypertension secondary to traumatic hyphema] |
| Q72856838 | [Use of a non-mercurial diuretic derived from iso-indoline in the treatment of ocular hypertension] |
| Q71119814 | [Use of fluorescein angiography of the papilla in the evaluation of patients with chronic glaucoma and ocular hypertension] |
| Q80145997 | [Usefulness of a glaucoma and ocular hypertension screening strategy in primary care] |
| Q68069837 | [Very early neuroretinal and functional changes in ocular hypertension] |
| Q69142660 | [Visual evoked potentials in glaucoma and ocular hypertension] |
| Q77366356 | [What would you do? Borderline ocular hypertension, visual field changes, and papillary atrophy in a 65-year-old patient] |
| Q95496971 | [When and how we start the treatment in patients with ocular hypertension or in glaucoma suspects?] |
| Q35403481 | c-Jun N-terminal kinase 3 expression in the retina of ocular hypertension mice: a possible target to reduce ganglion cell apoptosis |
| Q47912015 | α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model |